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ABSTRACT
A review of existing approaches to platinum drug discovery highlighted the
need for new methods to perform mechanism-based, high-throughput screening of
platinum complexes.
A new solution phase screening method was based on the importance of high
mobility group (HMG) domain proteins in the cytotoxicity of cisplatin. Platinum
compounds were evaluated based on their ability to form DNA adducts that bind
specifically to HMG-domain proteins. A mixture of platinum amino acid complexes
was prepared and combined with DNA to form platinum adducts, some of which were
recognized by HMG1 in a gel shift assay. In order to identify the platinum complex(es)
responsible for this behavior, a sublibrary synthesis and screening approach was
employed. After three iterations of sublibrary synthesis and screening, [Pt(lysine)C12](Kplatin) was identified as an (N,O)-chelated platinum(II) complex with DNA adducts
recognized by HMG-domain proteins. Kplatin and analogous (N,O)-chelates were less
toxic towards HeLa cells than cisplatin, presumably because of charge considerations.
A solid-phase assay was envisioned in which platinum-modified DNA could be
covalently linked to a solid support, and the binding of a fluorescently labeled HMG-
domain protein measured to predict the cytotoxicity of the platinum complexes. A
fluorescent HMG-domain protein was generated by expressing HMG1 as a fusion with
the green fluorescent protein (GFPuv). The product HMG1-GFPuv retained the
fluorescence and DNA-binding properties of its protein components.
To screen platinum complexes for biological activity in human cancer cells, a
transcription inhibition assay was developed. A stable HeLa cell line was generated
with doxycycline-inducible enhanced green fluorescent protein (EGFP). The effect of
platinum complexes and other cytotoxic agents on EGFP expression was assessed.
Most cytotoxic agents including trans platinum complexes stimulated EGFP
transcription, whereas cis platinum complexes inhibited EGFP expression in a dose-
dependent fashion. Transient transfection of the HeLa cells with testis-specific HMG
enhanced the inhibitory effect of cisplatin. A second reporter gene assay using a
fluorescent -lactamase substrate demonstrated the inhibition of gene expression by
cisplatin but not by ineffective platinum complexes.
Thesis Supervisor: Stephen J. Lippard
Chairman, Department of Chemistry and
Arthur Amos Noyes Professor of Chemistry
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Overview
This dissertation consists of three chapters and one appendix. Chapter 1 reviews
methods for screening platinum complexes for cytotoxicity. Chapter 2 describes a
solution-phase screen of platinum-amino acid complexes. Chapter 3 introduces two
cell-based methods for rapidly assessing platinum cytotoxicity. Finally, Appendix A
describes the fluorescent labeling of an HMG-domain protein.
Chapter 1 evaluates various methods, including those fully described in
subsequent chapters, for their utility in screening combinatorial libraries of platinum
complexes. It introduces the major in vitro, cell-based and in vivo approaches to
assessing the cytotoxicity of platinum complexes and describes the challenges in
improving screening methods.
Chapter 2 outlines the current understanding of the mechanism of action of
cisplatin with an emphasis on the role of HMG-domain proteins. A screening protocol
exploiting the importance of the platinum-DNA-HMG interaction for cytotoxicity is
proposed. The results of screening a mixture of platinum-amino acid complexes for the
binding of their DNA adducts to HMG1 are presented. The identification of the (N,O)-
chelated [Pt(lysine)C12] compound Kplatin, and subsequent studies of the in vitro and
cytotoxic behavior of Kplatin and analogues, are described.
Chapter 3 describes the use of reporter genes to predict and understand the
cytotoxicity of platinum complexes. After reviewing the effect of DNA damage on
reporter gene expression in mammalian cells, several new screening methods based on
the inhibition of gene expression by active platinum complexes are described. It is
shown that platinum complexes inhibit inducible EGFP transcription in HeLa Tet-On
Overview
cells and that this inhibition is well correlated with cytotoxicity. The enhancement of
EGFP transcription by other cytotoxic agents, the effect of tsHMG expression on the
assay, and the mechanistic implications of the results are also discussed. A second
platinum screening method using 03-lactamase as a reporter gene with a fluorescent
substrate is also described.
Appendix A reports several attempts to fluorescently label HMG-domain proteins
for use in solid-phase in vitro screening methodologies. The cloning, expression and
purification of the fusion of HMG1 with the GFPuv is described. The fluorescence and
DNA-binding activity of the resulting HMG1-GFPuv is also demonstrated.
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Chapter 1
Methods for Screening the Potential Antitumor Activity
of Platinum Compounds in Combinatorial Libraries*
1.1 Introduction
The success of cisplatin and carboplatin in treating cancer, combined with the
intrinsic and acquired resistance of many tumors to traditional platinum chemotherapy,
have generated considerable interest in developing next-generation platinum drugs.
Since the discovery of the antitumor activity of cisplatin, researchers have reported the
synthesis, characterization, and antitumor activity of thousands of platinum
compounds [1,2]. Recent developments include novel multinuclear platinum(II) and
orally active platinum(IV) complexes [3,4].
The advent of combinatorial chemistry has had a major impact on drug discovery
[5-7], but has not yet facilitated the search for new cisplatin analogues. To date there is
only one published report of a molecular diversity approach to platinum drug
discovery [8]. One reason for this situation is that the field of combinatorial chemistry
has evolved almost exclusively from organic chemistry [6,9-11]. Methods for
combinatorial synthesis of inorganic compounds, with the exception of solid-state
materials, have been developed only in a few laboratories [8,12]. It should be possible,
however, to apply the advances made by organic chemists in parallel synthesis,
automation and chemoinformatics to the generation of libraries of platinum complexes.
* A slightly modified form of this chapter was submitted for publication in 30 Years of
Cisplatin-Chemistry and Biochemistry of a Leading Anticancer Drug; B. Lippert, ed., Verlag Helvetica
Chimica Acta: Basel.
Chapter 1
In order for new platinum drugs to be discovered by a combinatorial approach,
there must be suitable screening protocols to identify "hits" from platinum libraries
[5,7]. The best screening methods accurately predict activity, are fast and simple, and
can be run in a high-throughput environment. A mechanism-based screen that detects
the interaction with a target molecule is ideal, but mechanistic studies of platinum
drugs have not yet identified a single critical target. Aside from general agreement that
DNA binding is required for cisplatin activity, there is little consensus about the
biologically relevant interactions that cause tumor cell death. It has therefore been a
challenge for researchers to develop a rational strategy for the synthesis of platinum
compounds having better anticancer activity than cisplatin.
There are three major approaches to assessing the potential activity of a
chemotherapeutic compound prior to human clinical trials. In vitro assays, either
solution- or solid-phase, are often used early in the screening process, especially when a
biologically relevant molecular interaction has been identified. Studies in cultured
mammalian cells are employed to predict the activity of a compound. If a compound
shows promise in such in vitro and cell-based assays, then it is tested extensively in
animals before proceeding to humans. The remainder of this chapter discusses these
three methods as potential routes to identifying active platinum compounds from
combinatorial libraries.
1.2 In vitro screening methods
In vitro methods are not widely used to predict the antitumor activity of platinum
compounds. Until it is determined what factors render a specific platinum-DNA
adduct cytotoxic, the in vitro screens for platinum drugs will be limited. Because a
good platinum drug must form DNA adducts, preliminary screening methods have
been employed which measure DNA binding alone as a measure of potential antitumor
activity. In one such study [13], the DNA binding of palladium and platinum
complexes having intercalative ligands was monitored by the quenching of ethidium
bromide fluorescence [14]. Upon metal-DNA binding, the intercalative ligand
displaced ethidium from DNA, causing a decrease in fluorescence. From the change in
fluorescence, DNA binding constants were determined for a series of fourteen
palladium(II) /phenanthroline/amino acid complexes. There was a correlation between
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DNA binding and both in vitro cytotoxicity and in vivo antitumor activity for the
compounds tested. The results are summarized in Table 1.1.
Table 1.1: Comparison of DNA-binding, cytotoxicity and antitumor activity of a
series of palladium(II) compounds [data from ref 13].
Complex Pd-DNA binding Cytotoxicity Antineoplastic
constant K x 10-6 Indexa Ratiob,c
(L/mol)
[Pd(phen)(leu)]C1 5.10 96.7 nd
[Pd(phen)(lys)]Cl 7.96 96.5 56
[Pd(phen)(met)]C1 5.16 95.0 nd
[Pd(phen)(ser)]C1 2.93 93.8 nd
[Pd(phen)(arg)]Cl 4.52 90.3 50
[Pd(phen)(his)]Cl 1.45 87.6 nd
[Pd(phen)(asn)]Cl 5.84 86.9 nd
[Pd(phen)(trp)]C1 3.35 83.7 nd
[Pd(phen)(gln)]C1 2.25 82.8 nd
[Pd(phen)(pro)]Cl 1.00 78.3 48.2
[Pd(phen)(tyr)]C1 4.90 77.9 nd
[Pd(phen)(ala)]C1 1.01 73.8 nd
[Pd(phen)(gly)]Cl 1.67 70.2 nd
[Pd(phen)(asp)] 0.75 37.8 nd
a Cytotoxicity index measures the percent dead MCF-7 cells counted by using
the trypan blue dye exclusion assay.
b Pure 615 mice implanted with sarcoma 180 were treated for nine days with 20
mg/kg/day. The ratio refers to the percent increase in lifespan, relative to
untreated controls.
C nd: Not determined.
Another report reveals, however, that in vitro DNA-binding assays are insufficient
to predict platinum antitumor activity [15]. Primer extension (Figure 1.1) was used to
identify specific adducts formed by platinum complexes on DNA in HeLa cells. The
DNA adduct profile correlated well with in vivo antitumor activity for cis- and trans-
DDP, [Pt(en)C12], and two acridine-tethered platinum complexes. When the complexes
were allowed to react with purified DNA in solution, there were no substantial
differences in adduct profiles between active and inactive compounds. This result
demonstrates that cell-based assays can be better predictors of in vivo activity than in
vitro assays, particularly when the in vitro screen does not require a unique,
mechanism-based molecular interaction.
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A. Isolate the DNA from platinum-treated cells.
Pt
= platinum
adduct
B. Denature the DNA and PCR-amplify a specific gene with a radioactively
labeled primer. Platinum adducts block the DNA polymerase.
*T1TF11fl--n
*TTTTTTm
------ -- N
C. Resolve the fragments on a denaturing gel.
Run sequencing lanes to identify the specific platinum adducts.
Pt G A C T
Figure 1.1: Identifying platinum-DNA adducts by primer extension.
- -
W-n
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Proteins that recognize cisplatin-modified DNA may effect the cytotoxicity of
cisplatin [16]. In particular, high-mobility group (HMG) domain proteins, which
specifically bind 1,2-intrastrand platinum-DNA cross-links, can mediate cisplatin
cytotoxicity by shielding the adducts from repair. One strategy for screening potential
platinum drugs, therefore, would be to evaluate a compound based on its ability to
form DNA adducts that bind specifically to HMG-domain proteins. This approach was
evaluated by screening a mixture of platinum-amino acid complexes for their ability to
bind DNA and, subsequently, HMG1 in a gel mobility shift assay [8]. The mixture was
prepared by combining potassium tetrachloroplatinate with two equivalents of an
equimolar mixture of 17 amino acids in water; the pH was maintained at 6 and, after
several days, the product mixture was evaluated without purification. The mixture was
combined with DNA to form platinum adducts, as confirmed by atomic absorption
spectroscopy. As illustrated in Figure 1.2, the mixture contained components that
shifted the platinated DNA upon addition to HMG1 in a gel shift assay.
HMG1 - + - + - + - +
P I .-- HMG1-DNA complex
~~UhI I -Free DNA
I II II II I
control K2 PtC14 cisplatin Pt-17 aa
Figure 1.2: Native polyacrylamide gel demonstrating the specific binding of HMG1
to a radiolabeled, platinated 123-bp DNA fragment. The DNA was modified with
platinum compounds or mixtures as indicated.
In order to identify the platinum complex or complexes responsible for this
behavior, a sublibrary synthesis and screening approach was employed. Five pools of
four amino acids each were used to prepare new mixtures to be screened by the gel shift
assay. After three iterations of sublibrary synthesis and screening, the platinum-lysine
complex Kplatin, shown in Figure 1.3, was selected. Kplatin has in vitro DNA-binding
properties similar to those of cisplatin. Its toxicity towards HeLa cells, on the other
hand, is almost 100-fold lower than that of the parent compound. Subsequent studies
with analogous (N, O)-chelated platinum-amino acid complexes further revealed that
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the ability of a platinum compound to form a ternary Pt-DNA-HMG1 complex does
correlate well with its toxicity towards HeLa cells [17].
CI
O -NH3 +
Figure 1.3: Structure of dichloro(L-lysine)platinum(II), or Kplatin.
Although the platinum-amino acid complexes do not show much promise as
cytotoxic agents, these results demonstrated the utility of in vitro screening methods to
survey the DNA-binding properties platinum compounds in a combinatorial manner.
Assuming that HMG-domain proteins are involved in the cisplatin mechanism of
action, then screening based on the Pt-DNA-HMG1 complex formation would be
mechanism-based. The gel shift assay, however, is neither fast nor convenient, so
alternative protein-DNA binding assays are required to adapt the method for high-
throughput screening.
A better approach would be to screen the molecular libraries on solid phase
supports [6,10,11]. Solid phase methods offer several advantages, allowing compounds
to be identified by immobilization and position in a binding assay. Solid-phase
screening can also be performed with the aid of robotics to increase throughput [7]. As
indicated in Figure 1.4, a fluorescently labeled HMG-domain protein would facilitate
the search for Pt-DNA-HMG binding by solid phase methodologies.
Accordingly, the Pt-DNA-HMG binding screen was implemented in the solid
phase by constructing a fusion of HMG1 with the green fluorescent protein (GFPuv)
[17]. As illustrated in Figure 1.5, the fusion protein HMG1-GFPuv binds specifically to
cisplatin-modified DNA covalently attached to a nylon membrane. The binding is
easily monitored by using a fluorescent microplate reader. The fluorescence readout,
corresponding to bound HMG1-GFPuv, correlates well with cytotoxicity for a series of
(N,O)-chelated platinum-amino acid complexes. The solid phase Pt-DNA-HMG1
binding method, or similar methods using other proteins that recognize platinated
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DNA, could be adapted to a high-throughput setting for the purposes of mechanism-
based screening of potential platinum antitumor drugs.
A. Covalently link DNA
to solid support.
C. Add fluorescently labeled
HMG-domain protein.
B. Allow platinum complex
to react with DNA.
D. Wash away unbound protein
and measure fluorescence.
Figure 1.4: A solid-phase approach to screening platinum compounds for specific Pt-
DNA-HMG interactions.
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Figure 1.5: Results of the solid-phase assay for Pt-DNA-HMG1 binding. A 19-base
pair DNA duplex was modified with cis- or trans-DDP and covalently linked to a
nylon membrane. The membrane was incubated with HMG1-GFPuv and washed
extensively. Bound protein was determined by measuring fluorescence retained on
the membrane.
1.3 Cell-based assays
Cell-based assays, particularly those using human tumor cell lines, provide a
relatively fast and inexpensive way to assess the in vivo activity of new compounds.
The success of a cell-based assay depends in part on the nature of the chosen cell line.
The NCI anticancer drug screening program tests compounds against a panel of 60
human tumor cell lines [18]. For practical reasons, individual laboratories have
generally selected only a few relevant cell lines for screening. There is no general
agreement about which cytotoxicity assay is the best predictor of anticancer activity.
In a clonogenic, or colony counting, assay, cells are treated with a prospective
anticancer compound, and their viability is determined by measuring the resulting
colonies. The clonogenic assay is widely used, partly because the ability to prevent cell
division is taken as an essential property of anticancer drugs [18]. The disadvantage of
the clonogenic assay is that it is time- and labor-intensive. It often takes more than one
week for visible colonies to form, and manual colony-counting is quite tedious [19].
Although computer-assisted colony counting methods are available, the clonogenic
assay is not particularly suited to high-throughput screening. Aside from time
considerations, in order to see subtle differences in percent survival, at least 100 cells
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must initially be seeded in an area large enough for individual colony formation. Thus,
the clonogenic assay cannot be miniaturized to the extent necessary for conveniently
screening large libraries of platinum compounds.
Several rapid, convenient cytotoxicity assays have been developed as alternatives
to the clonogenic assay. The neutral red assay measures uptake of a dye into cells, with
only viable cells binding the dye [20]. The microtetrazolium (MTT) assay correlates cell
count with the reduction of the yellow tetrazolium salt to purple formazan, a reaction
which occurs in the mitochondria of viable cells only [19,21]. Sulforhodamine B (SRB),
which is used in the NCI anticancer drug screening program, is an anionic
aminoxanthene dye that measures cell count by binding to cellular proteins [21]. In one
study MTT and SRB assays yielded quite similar cytotoxicity profiles for cisplatin and
other anticancer drugs in seven human tumor cell lines [21].
All three of the foregoing rapid cytotoxicity assays are suited to high-throughput
measurements by microplate reading, but it is necessary to wait several days following
treatment in order to measure cell viability. Moreover, these assays measure short-
term, 2-3 day, delays in cell growth, rather than the inhibition of cell division. In one
report, there was little correlation between results of the MTT and colony counting
assays for non-small cell lung cancer cell lines treated with mitomycin C or cisplatin
[18]. In another, very good correlation among the SRB, MTT and colony counting
assays was observed for 16 human ovarian carcinoma cell lines treated with cisplatin
[19].
Screening platinum complexes for cytotoxicity is not a mechanism-based
approach. Another cell-based screening method [22] is predicated on the observation
that mismatch-repair-deficient cells are less sensitive to cisplatin than wild type cells
[22,23]. A review of the role of mismatch repair proteins in cisplatin cytotoxicity reveals
that tumors resistant to cisplatin sometimes have mutations in one or more genes
encoding for such proteins [16]. A mismatch repair-deficient cell line constitutively
expressing GFP was mixed with a repair-proficient line and the heterogeneous
population treated with DNA-damaging agents. Five days following exposure, both
cisplatin and carboplatin enriched the GFP-expressing mismatch repair-deficient cell
population. The potential cytotoxicity of any platinum compound might therefore be
assessed by measuring the enrichment of GFP-expressing, mismatch repair-deficient
cells in the population. This method has a direct fluorescent readout that could be
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readily adapted to high-throughput conditions, but the 5-day delay necessary to see
population enrichment cannot be shortened. Because the method is based on a
proposed mechanism of resistance to platinum antitumor drugs, it is an advance over
methods that merely measure cell death.
Another, related method [24] uses a HeLa Tet-on cell line stably transfected with
the enhanced green fluorescent protein (EGFP) gene under the control of the
tetracycline-responsive element (TRE). Upon induction with doxycycline, the cells
express EGFP. Treatment with cisplatin and other effective platinum complexes caused
a dose-dependent decrease in EGFP expression. Treatment with trans-DDP and other
DNA-damaging agents led to a sharp increase in EGFP expression. Figure 1.6 shows
typical results of a 13.5-hour co-treatment of HeLa cells with platinum and doxycycline,
and Figure 1.7 plots platinum cytotoxicity versus EGFP inhibition. The method exploits
the apparent difference in cellular response to cisplatin adducts compared to other
forms of DNA damage. Although the somewhat low levels of EGFP expression require
cell lysis in order to quantitate fluorescence, with the use of improved fluorescent
reporter gene systems and better detection methods this approach could be adapted for
high-throughput work. The advantage of the EGFP induction assay is speed; the results
can be obtained overnight.
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Figure 1.6: Effect of a 13.5-hour cis- or trans-DDP treatment on doxycycline-inducible
EGFP expression in HeLa Tet-on cells. The fluorescence values were divided by total
protein to correct for variations in cell count.
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Figure 1.7: IC50 versus LC50 values for HeLa cells treated with a series of platinum
complexes. LCso was determined by a colony counting assay. IC,, was the platinum
concentration at which EGFP expression was reduced to 50% of control.
Another reporter gene assay has also been used to screen platinum compounds.
The fluorescent compound CCF2-AM, depicted in Figure 1.8, emits green fluorescence
when intact but blue light upon cleavage with p-lactamase [25]. The compound is
readily taken up by cells and, because of the enzymatic amplification, very low
concentrations of the I-lactamase reporter gene can be detected. Figure 1.9 reveals that
cis-DDP, to a much greater extent than trans-DDP, inhibits inducible p-lactamase
expression as measured by CCF2 cleavage in a Jurkat cell line. This assay is performed
in an automated high-throughput setting, and the results can also be obtained overnight
[24].
Chapter 1
CO 2AM
Cytoplasmic esterases
409 nm
CCF2
409 nm 447 nm
FRET 520 nm
/
CO2
P-Lactamase
HC~~~
0
H zN C 2-CO2-
Figure 1.8: Cleavage of the fluorescent reporter CCF2-AM in cells expressing f-
lactamase.
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Figure 1.9: Effect of a 20-hour cis- or trans-DDP treatment on carbachol-inducible i-
lactamase expression in Jurkat cells. The gene expression was determined by
measuring the cleavage of the fluorescent dye CCF2-AM.
These new reporter gene cell-based techniques represent the beginning of a new
era in platinum drug screening in cells. Instead of merely measuring cytotoxicity, the
new methods screen compounds for cellular effects specific to biochemical changes
induced by platinum antitumor drugs. The methods are also convenient and readily
adaptable to high-throughput settings. In both the mismatch repair and reporter gene
induction assays, the major disadvantage is that stable cell lines expressing reporter
genes must be constructed. Because it can take up to several months to obtain stably
transfected cell lines, it is necessary to choose cell types judiciously before proceeding
with screening.
1.4 In vivo screening methods
Animal models are frequently employed to assess the antitumor activity of new
platinum compounds. Often, mouse tumors such as mammary, lung or colon
carcinomas are used. In other cases human solid tumor xenografts are grown in
immune-deprived mice for drug screening. Although it can be argued that the efficacy
of a compound against tumors in mice may not predict its activity in humans, the
pharmacokinetic and toxicity properties of a new compound must be evaluated in
animals before proceeding with human clinical trials [26].
Although animal models can provide important information regarding the
bioavailability and pharmacology of potential anticancer drugs in mammals, they are
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not always accurate predictors of activity against human tumor cells. In one report [27],
the activity of a series of isomeric [1,2-bis(difluorophenyl)ethylenediamine]dichloro-
platinum(II) compounds was evaluated in MXT murine mammary carcinomas in vivo;
the same compounds were also tested against several human cell lines in culture. The
in vivo screen revealed a 2,6-difluorosubstituted compound to be the most active,
whereas the 2,4-difluorosubstituted compound was most active against the human
breast cancer cell lines. It was concluded that the mouse mammary carcinoma is not an
appropriate model for human breast cancers. Extreme caution must be employed when
animal tumor results are used to predict activity in human tumors.
Xenografts in mice of human cancer cell lines can serve as good models for human
tumors. In one report [28], a panel of eight human ovarian carcinoma cell lines and
companion xenografts were used to screen cisplatin, carboplatin, tetraplatin and
iproplatin. Overall, there was good correlation between the cell-based and xenograft
assays. This report not only demonstrates that xenografts can be good models for
human tumors, but also that human cell line assays can predict the activity of a
platinum compound approximately as well as xenograft studies. In most cases, it
would seem prudent to use human cell line assays as preliminary screens of platinum
compounds before moving on to animal studies.
Although it is essential to test promising compounds in mice and other animal
models prior to human trials, it is economically, ethically and often scientifically
preferable to use cell-based and in vitro approaches to eliminate inactive compounds
before commencing animal trials. Clearly, animal models are not an appropriate screen
for combinatorial libraries of platinum complexes; they should be used to study further
the promising leads identified by high-throughput methods.
An alternative in vivo approach to screening platinum complexes was recently
described [29]. A series of diamine platinum(II) complexes was applied to cucumber or
maize roots; the root growth inhibition indicated the cytotoxicity of the compound.
Because the root growth inhibition results correlated with the antitumor activity of the
complexes in mice, it was proposed that plant roots would afford inexpensive and rapid
screens for platinum compounds. Although the plant-based screening method is
unique and inexpensive, it is not an ideal approach to identifying platinum drugs to
treat human cancers. Given that even the selection of human tumor cell lines can affect
the results of a cytotoxicity assay, it seems unlikely that any plant cell line would
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suitably model human cancer. This method could be used as a very preliminary screen
for general cytostatic activity, but it is more laborious than any of the high-throughput
cell-based assays; the root length must be measured by hand daily for three days.
1.5 Conclusions
Although the field of medicinal chemistry has been revolutionized by the advent
of combinatorial synthesis and high-throughput screening, application of these
methodologies for platinum drug discovery and lead optimization is in its infancy. In
part, new methods for inorganic combinatorial synthesis must be devised. This process
can be accelerated by exploiting the recent advances in organic small-molecule
combinatorial chemistry. Also, new mechanism-based methods for screening platinum
compounds must be developed with a focus on speed and automation. The three
reporter gene assays described in this chapter [22,24], as well as the Pt-DNA-HMG1
binding assays [8,17], represent the beginning of a new trend toward mechanism-based
screens for platinum compounds. It would be especially useful to have more solution-
or solid-phase in vitro approaches to predicting platinum cytotoxicity. In order to
develop screening methods, however, a greater understanding of the biochemistry of
platinum antitumor activity is essential. When there is compelling evidence for the role
of a specific platinum-DNA-protein interaction in platinum cytotoxicity, for example,
then a high-throughput, mechanism-based screening method will surely follow.
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Chapter 2
A Mechanism-Based, Solution Phase Method for
Screening Combinatorial Mixtures of Potential Platinum
Anticancer Drugs*
2.1 Introduction
Cisplatin is used to treat testicular and other tumors. Its mechanism of action is
not entirely understood, but it is generally accepted that the drug binds primarily to
DNA, inhibiting replication and transcription and triggering programmed cell death
[1]. The major cisplatin-DNA adducts are the 1,2-d(GpG) and -d(ApG) intrastrand
cross-links, which bend and partially unwind the double helix [2,3]. An x-ray crystal
structure of duplex DNA containing the major d(GpG) cisplatin adduct was recently
obtained at 2.6 A resolution [4]. Two solution NMR structures of duplex DNA
containing the major d(GpG) adduct were also reported [5,6]. The resulting altered
structure serves as a recognition site for the binding of cellular proteins, many of which
contain one or more high-mobility group (HMG) domains [7]. Results from our
laboratory and others indicate that most HMG-domain proteins bind specifically to
cisplatin-modified DNA [8-15], further bending the duplex [16,17]. The platinum-
DNA-protein complex could in principle interfere with the natural function of the
HMG-domain protein [11]. There is convincing evidence that HMG-domain proteins
can block the excision repair of the major cisplatin adducts in vitro [18,19]. Moreover,
studies in Saccharomyces cerevisiae have demonstrated that Ixrl, an HMG-domain
" This chapter has been published in a slightly altered form in Journal of Biological Inorganic Chemistry
1998, 3, 74-80.
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protein, mediates the sensitivity of yeast to cisplatin and that this property is a
consequence of shielding of the adducts from excision repair [10,20]. This repair
shielding mechanism is supported by a recent report that overexpression of HMG2
sensitizes the lung adenocarcinoma cell line PC-14 to cisplatin [21].
Because the significance of HMG-domain proteins in mediating cisplatin
cytotoxicity is supported by several lines of experimental evidence, we decided to use
the binding of HMG1 to platinated DNA as a method to screen new platinum
compounds for cytotoxic and, ultimately, anticancer activity. To initiate this work, a
pool of seventeen naturally occurring amino acids was chosen. Platinum-amino acid
chemistry has been extensively investigated [22-24]. Amino acids coordinate to
platinum through nitrogen, oxygen and sulfur donors, and a single amino acid can bind
to platinum(II) in a monodentate, bidentate or tridentate fashion. The binding of more
than one amino acid to a single platinum atom and the potential formation of geometric
isomers further contribute to the molecular diversity of this class of compounds. A
priori it seemed likely that some platinum-amino acid complexes would react with DNA
to induce favorable interactions with HMG-domain proteins and therefore be potential
antitumor drug candidates. There have been only a few studies of the antitumor
properties of platinum-amino acid compounds [25-32]. A comprehensive investigation
of the potential activity of this class of compounds has not been carried out.
Since it is laborious to screen hundreds of individually prepared platinum-amino
acid complexes for their ability to induce DNA-HMG domain binding, we applied a
molecular diversity approach to search for appropriate candidates. There have been
several reports of screening mixtures of peptides for metal-binding activity [33-36] but
to our knowledge, there have been no published reports of the screening of pools of
metal complexes for biological activity. Molecular diversity approaches to drug
discovery often apply parallel solid-phase syntheses of large numbers of organic
compounds, followed by the simultaneous screening of all of the compounds for the
desired activity [37-39]. An alternate approach involves the solution-phase synthesis
and screening of a large mixture of compounds, followed by several rounds of sub-
mixture synthesis and screening to identify active components [40-42].
Because platinum-amino acid compounds can be prepared easily in aqueous
solution, mixtures of the complexes are well-suited to solution-phase synthesis. The
current understanding of the mechanism of action of platinum antitumor drugs
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underscores the importance of the ternary platinum-DNA-HMG-domain interaction for
anticancer activity. We thus employed a solution-phase, mechanism-based method to
screen platinum-amino acid compounds for the in vitro markers of anticancer activity.
In the first phase of the screening, a pool of platinum-amino acid complexes was formed
and used to modify DNA in aqueous solution. This pool was then screened by the gel
electrophoretic mobility shift assay to detect Pt-DNA-HMG-domain binding. In the
second phase, sub-mixture synthesis and screening were employed to identify, by the
same assay, the compounds present in the ternary complex.
2.2 Experimental
Cisplatin was obtained as a gift from Johnson-Matthey. Deionized water, purified
with a MilliQ system (Millipore), was used for all aqueous procedures. Recombinant
rat HMG1 [8], HMG1 domain B (HMGdomB) [43], HeLa cell-free extract [44],
recombinant mouse testis-specific HMG [14,45] and a 3'-end labeled 123-bp DNA
fragment [43] were prepared as described. The DNA was radiolabeled after
modification by platinum.
2.2.1 Physical Measurements.
Electronic spectra were recorded on a Varian Cary 1E UV-visible
spectrophotometer. Infrared spectra were measured by using KBr pellets on a BioRad
FTS-7 FT-IR 3200 spectrophotometer. 195Pt NMR spectroscopy was performed on a
Varian VXR-300 spectrometer, and referenced to K2PtC14 (0.1 M in 1 M HCl) as an
external standard at 8 -1624. Platinum concentrations were determined with a Varian
atomic absorption spectrophotometer AA-1475, equipped with a graphite tube atomizer
GTA-95. Standard solutions of potassium hexachloroplatinate(IV) were used to
calibrate the instrument. High performance liquid chromatography was performed
with a Perkin Elmer Series 4 liquid chromatograph, equipped with an LC-95 UV/visible
spectrophotometer detector set to 260 nm. MALDI-TOF mass spectra were obtained by
C. Costello and K. Tang (Boston University Medical School Mass Spectrometry
Resource) using a Finnigan MAT Vision 2000 instrument operated in the positive ion
reflectron mode, at 5 kV accelerating voltage, with 4 kV postacceleration at the detector.
The detector was equipped with a 337 nm LSI nitrogen laser, and the 3-
hydroxypicolinic acid matrix was doped with ammonium citrate. X-ray
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crystallography was performed by Dr. Peter Fuhrmann on a Siemens SMART/CCD X-
ray diffractometer with Mo Koc radiation (X = 0.71073 A). The structure was solved by
direct methods and refined on F2 by using the SHELXTL software package.
2.2.2 Synthesis of Mixtures of Platinum-Amino Acid Complexes.
In a typical procedure, an 80 mM aqueous solution of K2PtCl 4 was prepared, and
an equimolar mixture of L-amino acids (Sigma) was added to yield a 160 mM total
amino acid concentration. The solution was stirred at room temperature for 5-7 days;
sodium hydroxide solution was added 4-6 times daily to maintain a pH of 6. The
reactions were terminated by freezing the solutions when the pH was stable at 6 for 12
hours. The product mixtures were used without purification.
2.2.3 Preparation of Kplatin.
An aqueous solution of 160 mM L-lysine and 80 mM K2PtC14 was stirred at room
temperature. The pH of 6 was maintained by the addition of sodium hydroxide
solution several times daily, and after one week the solution was cooled to 00 C to
precipitate the yellow product. The precipitate was recrystallized from water by slow
evaporation. FTIR (cm'1, KBr pellet): 3242, 3189, 3125, 1643, 1613, 1514. UV-vis ( max,
nm, H20): 290 sh, 325, 391 sh. 195Pt NMR (8, H20): -1634. Anal. Calcd for
PtC12C60 2N2H14-2.5 H20: C, 15.76; H, 4.19; N, 6.13. Found: C, 15.53; H, 3.36; N, 6.01.
2.2.4 Modification of DNA with Platinum Compounds.
The 123-bp DNA was dissolved in 10 mM sodium phosphate, pH 6.8, at a
nucleotide concentration of 60 gM. Platinum compounds or mixtures were dissolved in
water and cleared by centrifugation at 10,000 x g; the resulting platinum solution was
added to DNA at the appropriate rf (formal platinum: nucleotide ratio) and the reaction
was incubated at 370C for 14 h. The DNA was precipitated with ethanol and the pellet
was washed to remove unbound platinum. The rb (bound platinum: nucleotide ratio)
was determined by atomic absorption and UV-visible spectrophotometry.
2.2.5 Modification of a Pentadecanucleotide with Kplatin.
A 15-mer, d(CCTCTCTGGTTCTTC), was modified with cisplatin, purified and 5'-
end-labeled as previously described [43]. To prepare a Kplatin-modified 15-mer, the
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oligonucleotide was incubated with 1.2 equiv of Kplatin in water for 24 h at 370 C. The
products were purified by anion-exchange HPLC on a Dionex Nucleopac PA-100
column (9 x 250 mm) with a solvent system of 25 mM ammonium acetate, pH 6.0, in
10% aqueous acetonitrile and a 30 min, 1 mL/min, gradient of 0.25-0.35 M NaC1. The
products, designated 15K1 and 15K2, were eluted from the column at 12.28 and 13.29
min, respectively. The two products were extensively dialyzed against water in
Spectra/Por 7 tubing, 1000 MW cutoff (Spectrum).
2.2.6 Gel Mobility Shift Assays.
A mixture of 32 P-labeled 123-bp DNA (104 cpm) with 2 gg of unmodified,
unlabeled chicken erythrocyte DNA was diluted to a total volume of 10 RL in a buffer of
4% (v/v) glycerol, 10 mM magnesium chloride, 50 mM potassium chloride, 1 mM
EDTA, 1 mM spermidine, 0.05% (v/v) Nonidet P40, 0.2 mg/mL bovine serum albumin,
and 10 mM HEPES pH 7.9. HMG1 (1 gg) was present as indicated. Samples were
incubated on ice for 20 min, followed by the addition of 0.5 jgL of loading dye, yielding
a final concentration of 5% (v/v) glycerol with 0.01% (w/v) bromophenol blue and
0.01% (w/v) xylene cyanol. Samples were loaded onto pre-run, pre-equilibrated (4°C)
6% native polyacrylamide gels (29:1 acrylamide:bis) and run in 45 mM Tris borate, 1
mM EDTA, pH 8.3 at 300 V for 3 h. After electrophoresis, gels were dried, visualized by
autoradiography (Kodak X-Omat film) and quantitated by using a PhosphorImager
(Molecular Dynamics). The mobility shift assay was performed on the 15-mer
essentially as described [43]; the double stranded 15-mer was used at a final
concentration of 10 nM.
2.2.7 Sequencing, Digestion and Extension of DNA Fragments.
A singly 5'-end labeled 82-bp DNA fragment was prepared from 123-bp DNA as
previously described [43]. An aliquot of the 82-bp fragment was analyzed by Maxam-
Gilbert sequencing. The remaining radioactive 82-bp fragment was combined with
carrier calf thymus DNA and cisplatin (rf 0.035) or Kplatin (rf 0.06) in 10 mM sodium
phosphate, pH 6.8. The reactions were incubated for 14 h at 370C and precipitated with
ethanol. The platinum-DNA adducts were characterized by T4 DNA polymerase
digestion followed by sequenase extension [46]. The final products of the reactions
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were dissolved in formamide loading dye and separated on a denaturing
polyacrylamide gel.
2.2.8 Modified Western Blots.
Modified western blots were performed as previously described [47] with the
following modifications. HMG1 and HeLa cell-free extract were separated on an
SDS/PAGE 12% gel. Binding buffer was 30 mM HEPES-NaOH, pH 7.5, 10 mM MgC12,
0.25% (w/v) nonfat dry milk. Platinated or unplatinated 32 P-labeled chicken
erythrocyte DNA (1 x 106 cpm; 100-300 pmol) was used as a probe; unlabeled,
unmodified chicken erythrocyte DNA (10 gg/mL) was added as a competitor.
2.2.9 Cytotoxicity Assays Using HeLa Cells.
All tissue culture reagents were purchased from Gibco BRL. HeLa cells were
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10%
certified fetal bovine serum. In preparation for the cytotoxicity assay, 200 cells in 4 mL
of platinum-free media were distributed to each 6 cm tissue culture plate. The cells
were incubated for 18-24 h and then treated with platinum solutions. Two or more
plates were prepared for each data point. After a 24 h treatment, the media were gently
aspirated and the cells were washed with phosphate-buffered saline. The cells were
incubated in 4 mL of complete media for 7-10 days; the colonies were then stained with
0.1% methylene blue (Fluka) in 50% ethanol and counted.
A sample of Kplatin was submitted to the National Cancer Institute
Developmental Therapeutics Program In-Vitro Screen to be tested against a panel of 60
human tumor cell lines.
2.2.10 Modification of DNA with Kplatin analogs.
The Kplatin analogs [Pt(Arg)C12] or Rplatin, [Pt(N-acetyl-lysine)C12] or
NacKplatin, and [Pt(norleucine)C12] or Norplatin were synthesized by Dr. Christopher
Ziegler. For each platination reaction, 7 x 106 cpm of radiolabeled 123-bp DNA was
combined with 1 [tg of chicken erythrocyte DNA. The DNA was diluted in 200 gL of 20
mM sodium phosphate buffer, pH 6.8. The platinum complexes were dissolved in
water and added at the appropriate rf, and the reactions were incubated overnight at
Chapter 2
370 C. The DNA was then precipitated with ethanol and redissolved in water. A set of
nonradioactive reactions was run in parallel to measure rb.
2.3 Results
2.3.1 Synthesis and Screening of Platinum-Amino Acid Mixtures.
The gel mobility shift assay was used to probe the ability of DNA modified with
different pools of platinum amino acid complexes to bind to HMG1. A platinum-amino
acid mixture composed of 17 L-amino acids was prepared; C, M and H were excluded
in the initial screening because of their known ability to bind strongly to metal ions.
Figure 2.1 demonstrates that some of the DNA modified with the reaction product(s) of
[PtC 4]2- with the 17-amino acid mixture bound specifically to HMG1. To identify the
platinum complexes most responsible for this interaction, five platinum-amino acid
sub-mixtures, each containing four randomly selected L-amino acids, were synthesized
and assayed in a similar manner. Table 2.1 summarizes the results. The amino acid
ligands in the sub-mixtures which induced the most specific protein-DNA binding were
KFRQ and YSPG. An additional round of sub-mixture synthesis was then performed
by using combinations of three amino acids derived from these two pools. Since the
KFRQ sub-mixtures induced more specific DNA-HMG1 binding than the YSPG sub-
mixtures, with pools containing K being the best (Table 2.1), the three lysine-containing
sub-mixtures were further divided into two-amino acid sub-mixtures. The resulting
compounds were very promising in their ability to modify DNA in such a manner as to
cause HMG1 to bind selectively. The KK sub-mixture in particular, prepared from
K2PtC14 plus 2 equivalents of lysine, was comparable to cisplatin in its ability to form a
ternary platinum-DNA-protein complex. From the platinum-lysine mixture, we
recovered crystals of the active complex, [Pt(Lys)C12] hereafter referred to as Kplatin, a
known compound [48,49] having the structure illustrated in Figure 2.2 and summarized
in Table 2.2. Additional structural information is available as supplementary material
at http: / /link.springer.de /link /service /journals/00775 /supp /list98.htm.
HMG1 (1 tg) - + - + - + - +
U mW1
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.4-HMG1-DNA complex
4- Free DNA
SiI II II J
control K2PtC14 cis-DDP Pt-17 aa
rb  0.019 0.030 0.039
Figure 2.1: Gel mobility shift assay demonstrating the binding of HMG1 to a 123-bp
DNA fragment modified with a platinum-amino acid library.
Table 2.1: Binding of HMG1 to 123-bp DNA Modified with Various Platinum
Compounds and Mixtures.
Platinum compoundsa rb % Specific Bindingbc
none 0 0
K2 PtCl4  0.019 1.7
17-aa mixture 0.039 45.7
cisplatin 0.030 74.2
none 0.000 0
WINC 0.043 <0
LMHD 0.066 <0
TVAE 0.012 1.9
KFRQ 0.030 17.4
YSPG 0.014 18.9
cisplatin 0.030 77.0
none 0.000 0
SPG 0.011 5.2
YSG 0.011 6.4
YPG 0.016 19.2
YSP 0.014 18.5
YSPG 0.014 11.9
Cisplatin 0.030 74.4
None 0.000 0
KFRQ 0.030 23.0
FRQ 0.051 25.4
KFR 0.024 30.5
KRQ 0.036 34.0
KFQ 0.041 52.3
cisplatin 0.030 77.6
none 0.000 0
KR 0.022 17.1
KQ 0.036 14.8
KFQ 0.026 28.4
KF 0.032 33.6
KK 0.045 44.5
cisplatin 0.021 54.4
a Platinum-amino acid mixtures are indicated by the one-letter code for the
component amino acids.
b Using ImageQuant phosphorimager software, volumes were measured
for each full lane (Vf) and for the upper portion (shifted band) of the
lanes (Vu) where protein-DNA complexes were normally observed. %
shift = (Vu/Vf) x 100%.
% binding = (% shift)sample + HMG1 - (% shift)sample-HMG1.
c % specific binding = (%binding)sample-(%binding)unmodified DNA.
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Figure 2.2: ORTEP of Kplatin showing the 50% probability thermal ellipsoids and
atom labeling scheme for three molecules in the asymmetric unit.
Table 2.2: Crystal data and structure refinement for Kplatin.
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume, Z
Density (calculated)
Linear absorption coefficient
Absorption correction
Tmin/Tmax
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected
Independent reflections
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Observed reflections [I>2a(I)]
Final R indices [I>2o(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
C 6H 14 C12 N2 0 2Pt and 8 H2 0 per
asymmetric unit
1380.67
188(2) K
0.71073
orthorhombic
P212121
a=9.7825(2) A
b=18.1650(3) A
c=21.9086(3) A
3893.14(12) A3, 12
2.356 g/cm3
11.228 mm - 1
analytical
0.0936/0.3391
2624
0.30 x 0.24 x 0.10 mm3
1.46" to 28.260
-125h512, -24<k 14, -28<1<28
23791
8986 [Ri=0.0325]
Full-matrix least-squares on F2
8986/16/488
1.104
8133
R1=0.0267, wR2=0.0529
R1=0,0327, wR2=0.0556
-0.006(6)
0.494 and -2.555 e/A 3
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2.3.2 Stability of Kplatin in aqueous solution.
To measure the effects of temperature and incubation time on the stability of
Kplatin in aqueous media, a 195Pt NMR study was performed. The results are
summarized in Table 2.3. The major peak at 8 -1634, corresponding to the [Pt(Lys)C12]
species, and a secondary peak at 6-1410, corresponding to the [Pt(Lys)C1(H 20)]
species, were observed in all of the aqueous and phosphate-buffered solutions. The
peak at 8-1057, corresponding to [Pt(Lys)(H 20) 2]2+, was not observed in any aqueous
or phosphate-buffered solution. A subsequent study [50] indicated that the dichloride
is also the major Kplatin species present after incubation in either DMEM or DMEM
with 10% fetal bovine serum.
Table 2.3: 195Pt NMR analysis of Kplatin solutions (49 mM).
Solvent Temp Time (h) Percentc Percent Percent
(OC) [Pt(Lvs)Cl ,] [Pt(Lvs)Cl(HO)] [Pt(Lvs)(H 0) , 2 +
(8-1634) (8 -1410) (8 -1057)
dH20 37 24 86.7 13.3 0
dH20 37 48 90.6 9.4 0
dH20 70 24 89.9 10.1 0
dH 20 70 48 86.1 13.9 0
NaPia 25 0 88.2 11.8 0
NaPi 25 24 90 10 0
NaPi 25 48 87.2 12.8 0
NaPi 37 24 89.6 10.4 0
NaPi 37 48 90.3 9.7 0
NaPi 55 24 91.5 8.5 0
NaPi 55 48 85.6 14.4 0
NaPi 70 24 90.5 9.5 0
NaPi 70 48 52.1 47.9 0
dH20 + 1 25 24 36.4 63.6 0
equiv Agb
dH2 0 + 1 70 24 (after 24 39.7 60.3 0
equiv Ag h activation)
dH2 0 + 2 25 24 0 29.6 70.4
equiv Ag
dH2 0 + 2 70 24 (after 24 16.9 25.0 58.1
equiv Ag h activation)
a NaPi: 10 mM sodium phosphate buffer, pH 6.8.
b Kplatin solutions were activated by adding silver nitrate in water and incubating in the dark for
24 h at 250 C. The silver chloride precipitate was removed by centrifugation.
c Percentages were determined by approximate integrations of NMR peaks. Because the
relaxation time of the 195Pt nucleus is rapid and varies with ligand environment [51], these
results should not be considered exact quantitations of Kplatin species.
L- 
-
--
j -x 
---
LJ
(8 
-1634)
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2.3.3 Interaction of Kplatin with DNA.
To determine whether and how Kplatin modifies DNA, the complex was
synthesized, purified, and allowed to react with pBR322 DNA at an rf value of 0.09 for
various time periods. After incubation, the platinated DNA was purified on G50
Sephadex and the rb was measured by atomic absorption spectrophotometry. Figure
2.3 plots the amount of bound platinum per nucleotide as a function of time. After 24 h
at 37°C, the reaction was complete and rb = rf. An exonuclease mapping analysis [52]
using T4 polymerase [46] was then undertaken to determine the types of DNA adducts
formed by Kplatin, the results of which are presented in Figure 2.4.
0.1
0.08
0.06
rb
0.04 - .
0.02 -
0 4 8 12 16 20 24
time, h
Figure 2.3: Time course of the reaction of Kplatin with pBR322 DNA. DNA (0.22
mM) was combined with Kplatin, rf=0.09, and incubated in a 1 mM sodium
phosphate, 3 mM sodium chloride buffer, pH 6.8, at 370 C. At the specified times,
reactions were terminated by the addition of 0.2 M NaC1. Unbound platinum was
removed by spin filtration through G50 Sephadex.
Because the 3' to 5' exonuclease activity of T4 DNA polymerase is inhibited at the
site of bifunctional platinum adducts, bands appear in the gel corresponding to stop
sites at the 3' side of the lesions. The unmodified 82-bp DNA fragment has some
intrinsic stop sites, but modification with either Kplatin or, in a control experiment,
cisplatin resulted in the appearance of new stop sites on the sequencing gel. The major
new fragments generated by cisplatin on the 82-mer correspond to the d(AGG) and
d(GGAGG) sites; Kplatin induced stop sites at all of the d(AG) and d(GG) sites on the
82-mer. A different assay employing sequenase was used to test for the presence of
interstrand cross-links [46]. Briefly, an interstrand cross-link would covalently tether
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both strands of DNA after T4 polymerase digestion, allowing sequenase to extend them
back to their full lengths. The sequenase extension step did not notably alter the
appearance of any bands on the sequencing gel, however. Interstrand adducts therefore
do not comprise a significant fraction of Kplatin lesions on DNA.
G C
No Pt cis-DDP KPt GACTGACT
11 2 3114 5 6117 8 91110111213
~ ,..AGG
. ap " 4-AGGAGG
-4-AG
Figure 2.4: Denaturing 12% polyacrylamide gel revealing products of exonuclease
digestion of a platinum-modified 156-bp DNA fragment. Lanes 2, 5 and 8: DNA
digested by T4 DNA polymerase. Lanes 3, 6 and 9: DNA digested by T4 DNA
polymerase followed by Sequenase extension. Lanes 10, 11, 12 and 13: Maxam
Gilbert sequencing reactions performed on unmodified DNA.
Because the T4 DNA polymerase digestions indicated that Kplatin modifies
d(GpG) and d(ApG) sites, the products of the reaction of Kplatin with a 15mer
containing a single d(GpG) site were analyzed by ion exchange HPLC. The products
were eluted from the column in two distinct peaks, 15K1 and 15K2. Maxam Gilbert
sequencing of the oligonucleotides [53,54] confirmed that the two adjacent guanine sites
on 15K1 and 15K2 were modified. MALDI-TOF mass spectrometric analysis gave m/z
values of 4801 and 4809 for 15K1 and 15K2, respectively; the error for external
calibration was ±0.1%. The mass spectrometric data therefore match the expected m/z
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value of 4805 for an adduct formed by hydrolysis of the Kplatin chloride ligands
followed by coordination of the resulting {Pt(Lys)12+ fragment to the N7 atoms of
adjacent guanosines. It was expected that Kplatin would form two orientational isomers
[55] at a d(GpG) site on DNA because of its asymmetry. In these isomers, the lysine
side chain would be oriented toward either the 3' or the 5' end of the oligonucleotide.
2.3.4 Interaction of Kplatin-Modified DNA with HMG-Domain Proteins.
The binding of Kplatin-modified DNA to various HMG-domain proteins was
assessed in gel mobility shift assays. Figure 2.5 shows that Kplatin-modified 123-bp
DNA bound to HMG1 nearly as well as cisplatin-modified DNA and that the binding
increased with increasing rb. Similar results were observed with HMGdomB (Figure
2.6), tsHMG (Figure 2.7), and with DNA modified with Kplatin prepared from D-lysine
(Figure 2.8). The binding of duplex 15K1 and 15K2 to HMGdomB was quantitated as
shown in Table 2.4; the two isomers of Kplatin-modified DNA have approximately the
same affinity for the HMG domain. A modified western blot (Figure 2.9) revealed the
binding of cisplatin- and Kplatin-modified DNA to proteins present in a HeLa cell-free
extract. Both cisplatin- and Kplatin-modified DNA bound to HMG1 and several other
proteins in the cell-free extract. The control blot, probed with unmodified DNA, had no
bands (data not shown). Although Kplatin was selected from combinatorial libraries
based solely on its ability to induce the binding of DNA to HMG1, the compound is
comparable to cisplatin in causing DNA to bind to other proteins.
HMG1 (1 gg) - + - + - + - + + - + - +
S4 Protein-DNA
complex
- Free DNA
Modification none cisplatin Kplatin
rb  0.003 0.016 0.022 0.003 0.016 0.020
Figure 2.5: Gel mobility shift assay comparing the binding of HMG1 to 123-bp DNA
modified with varying levels of cisplatin and Kplatin.
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Figure 2.6: Gel mobility shift assay comparing the
DNA modified with cisplatin
binding of HMGdomB to 123-bp
and Kplatin.
Platinum I none I[ cisplatin I IKplatin I
rb
tsHMG (0.75 gg)
Figure 2.7: Gel
Protein-DNA
complexes
S Free DNA
0.003 0.016 0.022 0.003 0.016 0.020
- + - + - + - + - + - + - +
mobility shift assay comparing the binding of tsHMG to 123-bp DNA
modified with varying levels of cisplatin and Kplatin.
Platinum none cisplatin KplatinII
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Protein-DNA complex - ON
Free DNA - 0--
Platinum none cis-DDP L-KPt D-KPt
HMG1 (1 gg) - + - + - + - +
Figure 2.8: Gel mobility shift assay comparing the binding of HMG1 to 123-bp DNA
modified with cisplatin, L-Kplatin and D-Kplatin.
Table 2.4: Binding of HMGdomB to Duplex 15mer Site-Specifically Modified with
Cisplatin and Kplatin.
15mer
Cisplatin-modified
15K1
15K2
[HMGdomB],
nM
0
50
100
400
0
50
100
400
0
50
100
400
a % specific shift=(% shift)sample-(% shift)unmodified DNA
% Specific
Shifta
0
36.8
39.2
44.4
0
20.9
29.6
36.8
0
24.9
26.7
34.9
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Figure 2.9: Modified western blot analysis of platinated chicken erythrocyte DNA
binding to HeLa cell-free extract proteins. Lanes 1-4 are autoradiographs of the blots
and lanes 5-7 are Coomassie-stained proteins separated by SDS-PAGE. Lanes 1-2
were probed with cisplatin-modified DNA, rb=0.021. Lanes 3-4 were probed with
Kplatin-modified DNA, rb=0.016. Lanes 1, 3 and 6: HeLa cell-free extract. Lanes 2, 4
and 7: HMG1. Lane 5: molecular weight markers. A control blot using an
unmodified chicken erythrocyte DNA probe revealed no nonspecific protein-DNA
binding (not shown).
2.3.5 Kplatin Cytotoxicity Studies.
Because Kplatin induces the same protein-DNA interactions as cisplatin, it was
anticipated that Kplatin would be cytotoxic. A 24-h treatment of HeLa cells with
Kplatin did induce cell death, as shown in Figure 2.10. For a 24-h cisplatin treatments
the average LC5 0 = 0.50 ± 0.05 jiM; for Kplatin the average LC 50 = 59.2 ± 7.8 gM, where
LC50 is the dose that killed 50% of the treated cells. As Figure 2.11 demonstrates,
similar results were obtained when HeLa cells were treated with Kplatin prepared from
D-Lys, although the stocks of HeLa cells used in the experiments differed in overall
platinum sensitivity. Additionally, cisplatin-resistant HeLa cells [56] exhibited cross-
resistance to Kplatin.
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Figure 2.10:
100
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[Platinum], gM
Colony-counting assay comparing the toxicity of cisplatin and Kplatin
toward HeLa cells.
Figure 2.11:
0 20 40 60 80
[Platinum], jiM
Colony-counting assay comparing the toxicity of cisplatin
toward HeLa cells.
100
and D-Kplatin
The results of the National Cancer Institute Developmental Therapeutics Program
In-Vitro Screen indicated that for all but one human tumor cell line, the LC50 value of
Kplatin was greater than 0.1 mM; in the exceptional case, a colon tumor cell line KM12,
LC50 for Kplatin was 74 gM.
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Table 2.5 shows the effect of serum content in the medium on the cytotoxicity of
Kplatin. The cytotoxicity was fairly constant between 10%-50% fetal bovine serum, but
the survival doubled when the cells were treated in serum-free DMEM.
Table 2.5: Effect of serum content on Kplatin cytotoxicity in HeLa cells.
Percent Serum (v/v) Percent Survivala
0 26.9
10 12.1
20 10.0
30 13.5
40 16.5
50 11.7
a Cells were treated with 100 gM Kplatin
for 24 hours in DMEM with the
indicated percent fetal bovine serum.
Cells were then washed with PBS and
incubated in DMEM with 10% serum.
2.3.6 Pt-DNA-HMG1 binding activity of Kplatin analogs
Table 2.6 compares the calculated rf and measured rb values for chicken
erythrocyte DNA modified with the platinum complexes depicted in Figure 2.12.
Cisplatin reacted readily with DNA, whereas Kplatin and Rplatin were moderately
reactive, and NacKplatin was only slightly reactive. Subsequent studies [57] indicated
that NacKplatin and Norplatin were equally reactive with DNA. Figure 2.13 shows the
results of the gel shift assay using 123-bp DNA modified with four platinum complexes.
As expected, cisplatin- and Kplatin-modified DNA specifically bound HMG1. Rplatin-
modified DNA also bandshifted whereas NacKplatin, at rb=0.004 , did not. When DNA
was treated with a large excess of NacKplatin or Norplatin, the resulting platinated
DNA did bind HMG1 [57].
Table 2.6: Comparison of rf and rb values for chicken erythrocyte DNA treated with
platinum complexes.
Pt complex r, rb
cisplatin .025 0.019
Kplatin .025 0.007
Rplatin .025 0.007
NacKplatin .025 0.004
47
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Figure 2.12: Structures of (N,O)-chelated platinum(II) amino acid complexes.
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DNA modification, rb unmodified
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I cisplatin, 0.019 Kplatin 0.007 Rplatin, 0.007 NacKplatin, 0.0041
Figure 2.13:: Gel mobility shift assay comparing the binding of HMG1 to 123-bp
DNA modified with cisplatin and (N,O)-chelated platinum(II) amino acid complexes.
2.3.7 Cytotoxicity,of Kplatin analogs
Figure 2.14 shows that Kplatin and Rplatin were nearly equitoxic towards HeLa
cells, with LC 50 values of about 25 jM for a 24 h treatment. NacKplatin had no
apparent effect on HeLa cell division. The HeLa stock used for this experiment was
more sensitive than the stocks used in Figures 2.10 and 2.11. In a subsequent study,
using HeLa C27 cells (described in Chapter 3), Norplatin had an LC50 of 150 gM,
compared to 70 gM for Kplatin.
---- cisplatin
-Ul - Kplatin
- - Rplatin
- - A - - NacKplatin
- I i I , , , ,
S----------
0 20 40 60 80 100
[Platinum], gM
Figure 2.14: Colony-counting assay comparing the toxicity of cisplatin and (N,O)-
chelated platinum(II) amino acid complexes toward HeLa cells.
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0.1
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2.4 Discussion
The first goal of our study was to develop a mechanism-based screening method
to exploit molecular diversity for selecting new platinum anticancer drug candidates.
Based on the current understanding of the mechanism of action of cisplatin, we
screened a solution-phase mixture of platinum-amino acid compounds on the basis of
their ability to modify DNA and induce binding to HMG1. After several iterations of
sub-mixture synthesis and screening, a single platinum-lysine compound emerged, the
DNA-HMG-domain binding activity of which approached that of cisplatin.
The compound selected by the screen, [Pt(Lys)C12] or Kplatin, differs structurally
from the known effective platinum antitumor agents in that it is an (N,O) chelate rather
than a bis(amine). A related class of compounds contain the cis-[Pt(NH3) 2]2+ moiety
coordinated by bis(phosphonomethyl)-aminoacetate [58], but this ligand is lost upon
DNA binding unlike lysine in [Pt(Lys)C12]. Pure Kplatin had been previously
synthesized and structurally characterized [48,49]. Kplatin is stable for several days in
aqueous solution at physiological pH and temperature. Like cisplatin, in a reaction
with DNA it loses two chloride ligands and modifies purine bases. Because of their
asymmetry, intrastrand d(GpG) Kplatin cross-links afford two linkage isomers, a
property previously encountered for another asymmetric platinum compound, cis-
[Pt(NH 3)(NH 2C 6H5)C12] [55]. This complex similarly forms site-specific orientational
isomers with oligonucleotides. Kplatin was selected for its ability to induce binding
between DNA and HMG1, but like cisplatin, it also causes DNA to bind specifically to
both tsHMG and HMGdomB. Because HMG-domain proteins generally recognize bent
and otherwise distorted DNA structures [59], it is likely that Kplatin bends DNA in a
manner similar to that of cisplatin.
Another objective of this research was to evaluate the cytotoxic properties of
newly identified anticancer drug candidates. Although its interactions with DNA and
HMG-domain proteins mimic those of cisplatin, Kplatin is 100-fold less toxic than
cisplatin toward HeLa cells, and its activity against other human tumor cell lines is
comparably low. Kplatin has a different DNA adduct profile than cisplatin, forming
fewer specific d(GG) and d(AG) adducts required for HMG-domain protein binding.
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Another possibility is that Kplatin is not efficiently transported into cells. Although the
compound is charge neutral, its dipolar nature and the dangling E-amino group of the
lysine side chain may prevent diffusion through the cell membrane. Preliminary cell
uptake studies (K.E.S. and S.J.L., unpublished results) indicate that, at equitoxic doses,
Kplatin is present at much higher concentrations in whole cell digests than cisplatin.
This result suggests that the complex may be concentrated in the cell membrane where
it is unable to form toxic DNA adducts. Alternatively, if Kplatin were to enter the cell,
the amino acid ligand could be metabolized, resulting in a different and possibly less
active platinum compound. The similar activity of both D- and L-Kplatin would
discount this latter hypothesis, however, since the two enantiomers are unlikely to
undergo the same metabolic transformations. It is also possible that Kplatin
decomposes under physiological conditions, or that it reacts with components of the cell
growth medium. The 195Pt NMR results, however, indicate that dichloride species
predominates in aqueous solutions and in media with or without serum. Additionally,
serum enhances Kplatin cytotoxicity, discounting the possibility that serum
components irreversibly bind and inactivate the platinum.
The studies of the Kplatin analogs provide further insight into the cytotoxic
behavior of the (N,O) chelates. The (N,O)-chelated platinum-arginine complex Rplatin
resembles Kplatin in its ability to form DNA adducts that bind HMG1. Kplatin and
Rplatin were also equally toxic toward HeLa cells. Because they are both charge
neutral, (N,O)-chelated amino acid platinum complexes with positively charged side
chains, the amine and guanidinium residues of Kplatin and Rplatin probably do not
contribute significantly to the biological activity of the complexes. To test the effect of
side chain charge, NacKplatin and Norplatin were investigated. Both of these
complexes have a neutral side chain, but their overall negative charge inhibits binding
to anionic DNA. NacKplatin had no toxic effect on HeLa cells, whereas Norplatin was
about half as toxic as Kplatin. The DNA affinity of the two complexes is equal, but the
hydrophobic norleucine side chain may enhance the cellular uptake, and thus the
cytotoxicity, of Norplatin. The utility of the (N,O) chelates as cytotoxic agents is limited
because of charge considerations. A cationic side chain yields a neutral platinum
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complex that binds DNA, but the dipolar nature of the complex may inhibit cellular
uptake. On the other hand, a neutral side chain yields an anionic complex that does not
readily form the DNA adducts that are essential for cytotoxicity.
2.5 Conclusions
We have demonstrated that a solution-phase molecular diversity approach can be
used to identify small inorganic compounds that induce protein-DNA binding. After
several rounds of sub-mixture synthesis and screening, a moderately cytotoxic
compound having the desired in vitro binding activity was identified. The platinum-
lysine compound Kplatin is an (N,O) chelate, in contrast to the canonical platinum
antitumor drug family comprising cisplatin and carboplatin. Subsequent studies of
analogous (N,O) chelates indicated that the electrostatic properties of these complexes
limit their cytotoxicity.
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Chapter 3
Expression of Inducible Reporter Genes in Human
Cancer Cells in Response to Treatment with Cytotoxic
Agents
3.1 Introduction
A critical component of platinum antitumor drug discovery is the evaluation of
the cytotoxicity of new complexes [1]. To facilitate the screening of combinatorial
libraries of platinum complexes, fast, high-throughput assays are needed. Methods
utilizing cultured cancer cells are desirable because they provide essential information
about the uptake and metabolism of new compounds. The commonly used cytotoxicity
assays, however, are not ideal. Clonogenic or colony counting methods can take over
one week to yield results and are not suited for high-throughput screening [1]. Assays
employing dyes such as neutral red [2], microtetrazolium (MTT) [3] or sulforhodamine
B [4] can be performed with the aid of robotics for high throughput, but cells must be
incubated for several days before quantitation. The goal of this research was therefore
to develop rapid cell-based assays, suitable for high-throughput screening, that
accurately predict the cytotoxicity of platinum complexes.
Transcription, a key step in gene expression, seemed at the outset to be a suitable
focal point for assay development. The in vitro inhibition of replication and
transcription by platinum-DNA adducts is well-documented [5-8]. Platinum complexes
can inhibit promoter-driven gene expression in mammalian cells. In one study [9],
plasmids encoding the P-galactosidase reporter gene under the control of the CMV or
SV40 early region (SVER) promoter, were modified with cis- or trans-DDP and
transfected into mammalian cell lines. Cisplatin inhibited P-galactosidase transcription
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2-3 fold better than trans-DDP, an effect attributed to more efficient bypass of trans-DDP
adducts by RNA polymerase. In a series of transient transfection studies of CV-1
monkey cells, cis- and trans-DDP both inhibited reporter gene expression from various
promoters [10]. Cisplatin, unlike trans-DDP, better inhibited expression from strong
than weak promoters, suggesting that the targeting of highly expressed genes may
contribute to the cytotoxicity of the cis isomer. In mouse tumor cells cisplatin, but not
an equitoxic dose of trans-DDP, blocked transcription from the mouse mammary tumor
virus (MMTV) promoter [11]. It was suggested that structural features of cisplatin-
DNA adducts prevent chromatin remodeling and transcription factor binding, both
essential for transcriptional activation, consistent with the results of recent x-ray and
NMR studies [12-14].
Cisplatin and other DNA-damaging agents can also stimulate gene expression
from promoters implicated in resistance or apoptosis pathways. In mammalian cells,
DNA damage can induce p53-dependent apoptosis or an SOS-type response that results
in cell cycle arrest, DNA repair, and enhanced survival [15,16]. In mouse
erythroleukemia cells, c-myc-driven chloramphenicol transferase (CAT) expression was
enhanced by cisplatin [17]. Activation of c-myc has been implicated in cisplatin
resistance [18]. In melanoma cells, cisplatin and UV light both induce c-jun promoter
activity, which is correlated with apoptosis in many cell lines [19]. A review of the
effect of cisplatin on genes involved in the regulation of cell growth is available [20].
DNA damage also induces gene expression from promoters with no obvious role
in cytotoxicity or resistance. Transient and stable transfections of appropriate vectors in
HeLa cells revealed that cisplatin inhibited CAT expression from the SVER promoter
and the adenovirus 2 major late promoter (MLP), but induced expression from the
HIV-1 long terminal repeat (LTR) and adenovirus 5 E3 promoters [21]. Similarly, in
HeLa cells, mitomycin C and UV light increased HIV-1 LTR-promoted gene expression
by up to 150 fold [22]. In human and rat fibroblasts, cisplatin stimulated CAT
expression from the HIV-1 LTR promoter [23].
The promoter-specific effects of cis- and trans-DDP in mammalian cells imply that
a reporter gene assay could be used to screen novel platinum complexes for potential
cytotoxic activity. In addition to offering speed and convenience, a reporter gene assay
would measure responses to DNA damage, rather than the endpoint of cell death. Such
an assay could therefore be used for mechanistic studies as well as drug discovery.
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Until recently, reporter gene assays were not ideal for high-throughput screening.
The popular CAT and luciferase assays, for example, both require cell lysis followed by
substrate addition to monitor enzyme activity. A recent and widely used reporter gene
is the Aequoria victoria green fluorescent protein, or GFP [24-26]. Post-translational
cyclization of a Ser-Tyr-Gly tripeptide results in a stable, species-independent
fluorophore that requires no substrates or cofactors. GFP is a 238 amino acid protein
that emits 509 nm light when excited at 395 nm. Mutagenesis of the glycine and three
neighboring amino acids has generated functional GFP mutants with unique
fluorescence properties. The commercially available GFP variants such as the EGFP
(enhanced green fluorescent protein) contain humanized codons and are visible in
intact cells and tissues. Because GFP is not an enzyme, however, very low levels of GFP
cannot be detected over background autofluorescence. Also, nonexpressing cells cannot
be detected by fluorescence, so they must be measured by some other method in order
to correct GFP values for variations in cell plating. To overcome such problems
associated with GFP and other reporters, a fluorescence-based method using 0-
lactamase as a reporter enzyme was recently developed [27]. The fluorogenic substrate
CCF2-AM is readily taken up into the cytoplasm, where esterases convert it to the
membrane-impermeant substrate CCF2. Upon excitation with violet light, intact CCF2
emits green fluorescence, whereas the product of P-lactamase-catalyzed CCF2
hydrolysis emits blue light. It is thus possible to distinguish expressing blue cells from
nonexpressing green cells by their fluorescence color. The ratio of blue to green
fluorescence intensities is a measure of p-lactamase expression.
There have been only a few reports linking cytotoxicity and reporter gene
expression. One proposed screening method utilized mouse cells lines constitutively
expressing firefly luciferase or P-galactosidase [28]. Upon death the cell membranes
ruptured and released the reporter enzyme into the growth medium, where it could be
quantitated by adding substrate. Although this method detected cell death, it did not
take into account the influence of cytotoxic agents on reporter gene expression. In
another study [29], a series of antimycobacterial agents were screened for the ability to
inhibit GFP expression in M. tuberculosis. The results demonstrated that GFP inhibition
could be used to predict the activity of potential tuberculosis drugs. Another screening
method [30] is based on the observation that mismatch-repair-deficient cells are more
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resistant to some forms of DNA damage than wild type cells [30,31]. A mismatch
repair-deficient cell line constitutively expressing GFP was combined with a repair-
proficient line and the heterogeneous population treated with platinum complexes and
other DNA-damaging agents. Within five days of exposure, cisplatin and carboplatin
enriched the GFP-expressing mismatch repair-deficient cell population. The
cytotoxicity of any platinum compound might therefore be predicted by measuring the
enrichment of GFP-expressing, mismatch repair-deficient cells in the population.
To observe the effects of platinum complexes on reporter gene expression, we
utilized both constitutive and inducible promoters. For strong constitutive gene
expression, the CMV promoter was placed upstream of EGFP and p-lactamase in HeLa
and Jurkat cells, respectively. For inducible EGFP expression in HeLa cells, a Tet-On
system (Figure 3.1) was chosen [32], where the gene of interest (EGFP) was cloned into a
plasmid downstream of the minimal early promoter of the CMV (PminCMV). In the
presence of doxycycline, the tet-responsive transcriptional activator (rtTA) binds and
activates the tetracycline-responsive element (TRE), which in turn activates the CMV.
In that manner, the addition of doxycycline to the growth medium induces EGFP
expression. Inducible P-lactamase expression in Jurkat cells was achieved by using a
previously reported [27] cell line with the NF-AT-p-lactamase reporter and the G-
protein coupled muscarinic receptor under the control of the CMV promoter (M1-
GPCR/NFAT-bla or C2 Jurkat). Treatment of the cells with the muscarinic agonist
carbachol induced P-lactamase expression.
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Integrated copy of pTet-On regulator plasmid
PCMV rtetR 
--
\ +Dox rTet
rtTA -Dox
r~etRTranscription
TRE TminCMV EGFP
Integrated copy of pTRE response plasmid
Figure 3.1: Tet-On System for Inducible Gene Expression
3.2 Experimental
3.2.1 Materials
Tissue culture media and antibiotics were purchased from Gibco BRL. Tet System
Approved FBS, pEGFP-1, pTRE, pTK-Hyg, HeLa Tet-On cells and anti-GFP antibody
were obtained from Clontech. All restriction enzymes and T4 DNA ligase were from
New England Biolabs. Cisplatin and JM335 were obtained from Johnson-Matthey. All
other platinum complexes were provided by S. J. Lippard and coworkers.
Calicheamicin was donated by P. Dedon (MIT).
3.2.2 Physical measurements
Fluorescence spectra were recorded on a Hitachi F-3010 Fluorescence
spectrophotometer. All EGFP fluorescence microplate readings were obtained using a
Molecular Devices Fmax instrument equipped with a 485±14 nm excitation and a
538±25 nm emission filter. CCF2 fluorescence was measured using a Cytofluor 4000
microtiter plate fluorimeter with a 395±10 nm excitation filter and emission filters of
460±20 nm (blue fluorescence) and 530±15 nm (green fluorescence). In both cases the
emission values were corrected by subtracting readings from blank wells. Automated
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DNA sequencing was performed on an ABI Prism system at the MIT Biopolymers
Laboratory. Platinum concentrations, relative to a potassium hexachloroplatinate(IV)
standard, were determined with a Varian atomic absorption spectrophotometer AA-
1475, equipped with a graphite tube atomizer GTA-95. Phosphorimager analysis was
performed on a BioRad Molecular Imager.
3.2.3 Stable transfection of HeLa with a constitutive EGFP expression vector
The mammalian vector pEGFP-N1 was amplified in E. coli and purified by using a
Qiagen-500 kit. The plasmid was further purified by digestion with Plasmid-Safe
DNase (Epicentre Technologies). The pEGFP-N1 was linearized with EcoO109I, and the
reaction mixture was extracted with phenol and precipitated with ethanol.
HeLa cells were plated on 10-cm plates and grown to 60% confluence in DMEM
supplemented with 10% FBS, 100 gg/mL penicillin and 100 U/mL streptomycin. Two
hours before transfection, the cells were given fresh media.
To form calcium phosphate-DNA complexes [33], three aliquots of linearized
pEGFP-N1 were precipitated with ethanol; they contained 10, 25 and 50 gg of DNA,
respectively. The DNA pellets were air-dried and each was dissolved in 0.5 mL of 0.25
M calcium chloride. Each DNA solution was then added, dropwise with agitation, to
500 gL of 2x Hepes-buffered saline (HBS) solution. The DNA precipitates were
incubated at room temperature for 20 min and then distributed over the HeLa cells.
After a 16 h 37 0 C incubation, the cells were washed twice with PBS and given fresh
media. They were incubated for about 32 h before selection was begun.
To select for transfectants, the HeLa cells were maintained in media containing 0.8
mg/mL geneticin; the media was replaced every 48 h. After 4 days of selection, the
cells were split 1:10. After 16 days of selection, 14 resistant colonies were transferred to
a 24-well plate. The clones were maintained in selective medium and expanded until
frozen stocks could be prepared from the nine most viable cell lines. Two of the
putative transfected HeLa clones, and the parental HeLa cell line, were grown to
confluence and examined by fluorescence microscopy using an FITC filter.
3.2.4 Cisplatin treatment of EGFP-expressing HeLa cells
A pEGFP-N1-transfected HeLa clone and parental HeLa cells were grown to 70%
confluence on 10-cm plates. Cisplatin was dissolved in water and added to the cells for
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a 24 h treatment, after which the medium from each plate was collected. The cells were
washed with PBS, which was combined with the collected media. The cells were then
trypsinized and added to the appropriate collection tubes, which were centrifuged for 5
min at 350 x g. The cell pellets were resuspended in 1 mL of PBS and re-centrifuged
twice; the final pellets were each suspended in 1 mL of PBS with 10 gg/mL each of
pepstatin, leupeptin and aprotinin and 400 gg/mL of Pefablock. The cells were then
counted by using a hemocytometer, and their emission spectra at 509 nm were recorded
(395 nm excitation).
3.2.5 Measurement of EGFP half-life in stably transfected HeLa cells
A HeLa clone constitutively expressing EGFP was grown to 70% confluence on 10-
cm plates. Each plate was washed with 5 mL of DMEM deficient in methionine,
cysteine and glutamine. Each plate was then starved by treatment with 3 mL of DMEM
(no M, C, Q) with 15% dialyzed FBS (1000 MWCO, Sigma). After 30 min, 0.4 mCi of 35S
methionine/cysteine (Dupont NEN) and 2 mM L-glutamine were added to each plate
for a 90 min incubation. Each plate was then washed and given 10 mL of complete 10%
FBS DMEM.
For each time point, one plate of cells was washed with 5 mL of cold PBS. The
cells were then incubated on ice for 30 min in 1 mL of lysis buffer (50 mM Tris, pH 8,
150 mM NaC1, 0.5% NP40, 1 mM DTT, 10 gg/mL each of aprotinin, leupeptin, and
pepstatin, and 0.5 mg/mL Pefablock). The lysate was centrifuged for 10 min at 10,000 x
g at 4C. The supernatant was flash-frozen in liquid nitrogen and stored at -80C.
(Note: All of the following procedures were carried out at 40C and all
centrifugations were at 10,000 x g.)
The protein concentration in each cell extract was determined by using the BioRad
DC protein assay. The extracts were diluted to 0.64 mg/mL in lysis buffer. Each
sample was combined with 6 gL each of normal rabbit and mouse sera and 100 gL of
washed staph A (donated by M. Bogyo, H. Pleough laboratory). The tubes were rocked
for 45 min and then centrifuged for 10 min. The supernatant fractions were transferred
to new tubes and the procedure was repeated, but with 11 gL each of rabbit and mouse
serum. The cell extracts were thus depleted of components that nonspecifically bound
protein A and/or antibodies. The cleared cell extracts were then combined with 2 gL of
polyclonal anti-GFP antibody and rocked overnight. Each extract was then combined
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with 80 [tL of washed staph A, rocked for 1 h and spun for 30 s. The pellets were
resuspended in 200 gL of NET buffer (50 mM Tris pH 7.5, 150 mM NaCi, 5 mM EDTA,
0.5% NP40). After four cycles of centrifugation and resuspension, the suspensions were
transferred to new tubes and centrifuged for 30 s. The pellets were resuspended in 100
RL of SDS loading dye, boiled for 5 min and loaded on a 4.5% stacking, 10% separating
SDS polyacrylamide gel. The gel was soaked in Amplify (Amersham) to intensify the
signal for autoradiography.
3.2.6 Cloning of pTRE-EGFP
The gene encoding the enhanced green fluorescent protein (EGFP) was PCR-
amplified from pEGFP-1 to incorporate EcoRI and XbaI sites. The primers were as
follows, with restriction sites indicated in boldface:
Forward (EcoRI) primer:
5'-TCT CGA GCT CAA GCT TCG AAT TCT GCA GTC GAC GGT-3'
Reverse (XbaI) primer:
3'-ATT TCG CCG GCG CTG AGA TCT AGT ATT AGT CGG TAT-5'
The PCR reaction was performed in an EZStart 100 reaction tube (Molecular Bio-
Products). To the prepared reaction tube, 0.2 Vg of template DNA (pEGFP-1) and 0.5 gg
of top and bottom primers were added, with 5 U of Pfu polymerase (Stratagene) in a
total volume of 50 pL. The reaction cycles were as follows:
1 cycle: 94°C, 45 s.
25 cycles: 94°C, 45 s; 55 0 C, 45 s; 720 C, 120 s.
1 cycle: 72°C, 600 s.
The PCR product was precipitated with ethanol and digested with EcoRI and XbaI.
After heat-inactivation of the enzymes, the DNA was precipitated with ethanol.
The plasmid encoding the tetracycline-responsive element, pTRE, was amplified
in E. coli and purified with a Qiagen 500 column. The plasmid was then digested with
EcoRI and XbaI; the linearized vector was purified on a 1% agarose gel.
The EcoRI/XbaI digest of EGFP was combined with the EcoRI/XbaI digest of
pTRE and incubated for 16 h at 160C with T4 DNA ligase in the presence of 10 RM ATP.
The ligation mixture was transformed into chemically competent XL1-Blue cells and
plated on LB ampicillin agar plates. The resultant colonies were inoculated into LB
ampicillin media and grown to saturation; the plasmids were isolated by the boiling
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lysis method. The plasmid DNA was digested with BamHI and analyzed on a 1%
agarose gel. The two samples that possessed the expected 750-bp insert were purified
with a Qiagen 500 kit and digested with a series of restriction enzymes to verify that the
EGFP gene had been properly inserted. The products were analyzed on a 1% agarose
gel. The two plasmids were then submitted to the MIT Biopolymers facility for
automated DNA sequencing on the ABI Prism system. The primers were as follows:
Forward: 5'-ATA GAA GAC ACC GGG ACC GA-3'
Reverse: 3'-CT ACT CAA ACC TGT TTG GTG-5'
3.2.7 Transfection of HeLa Tet-on cells with pTRE-EGFP
The plasmids pTRE-EGFP and pTK-Hyg were amplified in E. coli, purified on
Qiagen 500 columns and linearized with SspI and HindIII, respectively. HeLa Tet-on
cells were cultured in DMEM with 10% FBS, 100 ptg/mL of penicillin, 100 U/mL of
streptomycin, and 400 gg/mL of geneticin. The cells were transfected using the calcium
phosphate method described in Section 3.2.3. To confer hygromycin resistance, each
plate of cells was transfected with 2 gg of linearized pTK-Hyg in addition to pTRE-
EGFP. The selective medium contained 0.4 mg/mL geneticin and 0.2 mg/mL
hygromycin. After 11 days of selection, 70 resistant colonies were transferred to 24-well
plates and expanded.
Forty-eight of the putative pTRE-EGFP transfected HeLa Tet-on clones, and the
parental HeLa Tet-On cell line, were grown to confluence on 35-mm plates and induced
with 4.3 gM doxycycline. Sixteen hours after induction, the cells were examined by
fluorescence microscopy using an FITC filter. Frozen stocks were prepared from twelve
green fluorescent clones.
Five of the selected clones were grown to 70% confluence on 10-cm plates. After a
16 h 4.3 gM doxycycline induction, each plate of cells was washed with PBS and lysed
in 250gjL of PBS with 2% SDS and 15 gg/mL of pepstatin, leupeptin and aprotinin.
Each lysate sample was passed five times through a 25 G 5/8 needle, boiled for five
min, flash-frozen in liquid nitrogen and stored at -80C. The total protein was
quantitated by using the BioRad DC assay, and a 100 jgg sample of each extract was
boiled in SDS loading buffer and run on a 4.5% stacking, 10% separating SDS
polyacrylamide gel. The proteins were transferred to nitrocellulose and probed with
the polyclonal anti-GFP antibody by Western blotting. For visualization, the blot was
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washed with an anti-rabbit antibody conjugated to horseradish peroxidase; the
chemiluminescent substrate luminol was then applied, and the blot was immediately
exposed to x-ray film for 2 min.
3.2.8 EGFP expression assay in HeLa C27
The selected HeLa C27 cells were maintained in DMEM supplemented with 10%
FBS, 100 gg/mL penicillin, 100 U/mL streptomycin, 0.4 gg/mL geneticin and 0.2
gg/mL hygromycin. Twenty-four hours before induction, the cells were distributed in
6-well plates such that they would be 60-70% confluent upon induction. Aqueous 0.4-
2.0 mM platinum solutions were prepared no more than 2 h before use, and platinum
concentrations were confirmed by atomic absorption spectroscopy. In a typical co-
treatment experiment, the platinum complexes were added to each well together with
21.6 gIM doxycycline. After a 13.5 h incubation, the cells were washed with PBS and
lysed by vigorous shaking in 125 gL of PBS with 0.5% SDS. The lysates were
transferred, using wide-bottomed pipet tips, to a black 96 well microplate (Corning
Costar) for fluorescence plate reading. A 4-gL aliquot of lysate was removed from each
sample and used in the Nano-Orange protein assay (Molecular Probes). The EGFP
fluorescence values were divided by their respective protein assay readings to correct
for variations in cell plating. The corrected fluorescence values were then normalized
relative to the control (unplatinated) samples. All samples were prepared in triplicate,
and the data was averaged with error bars representing one standard deviation.
3.2.9 Northern blotting of RNA from HeLa C27 extracts
For Northern blotting analysis, HeLa C27 cells were plated on 10 cm tissue culture
dishes and grown to 70% confluence. Parallel samples for the EGFP expression assay
were prepared in triplicate on 6-well plates. The cells were treated with the appropriate
cytotoxic agents and induced for 13.5 h with 21.6 giM doxycycline. RNA was isolated
from cell extracts by using the Biotecx Ultraspec-II kit. After agarose-formaldehyde gel
electrophoresis, the RNA was transferred to nitrocellulose and processed according to
standard procedures [34]. The blot was probed with random primer-labeled DNA
encoding EGFP and, as a control, human GAPDH (donated by D. Housman laboratory,
MIT). The blot was quantitated by phosphorimager analysis with a BioRad Molecular
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Imager, and EGFP values were corrected for loading by normalizing to the ubiquitously
expressed GAPDH.
3.2.10 Transient transfection of HeLa C27 with pcDNA3.1-tsHMG
The pcDNA3.1-tsHMG plasmid, and the control plasmid pcDNA3.1, were
obtained from Christina Eng, amplified in E. coli and purified on Qiagen 500 columns.
HeLa C27 cells were distributed on 6-well plates 24 h prior to transfection. Two hours
before transfection, when the cells were about 25% confluent, the growth medium was
changed. The cells were transfected with the circular plasmids by the calcium
phosphate method, with either 6 or 10 gg of plasmid per well. The precipitate was
washed away after 16 h, and the cells were incubated in fresh media for 48 h. The cells
were then co-treated for 13.5 h with cisplatin and doxycycline in fresh media, and the
EGFP expression assay was performed as described in Section 3.2.8.
3.2.11 Cytotoxicity and apoptosis assays
Jurkat C2 cells, obtained from Gregor Zlokarnik (Aurora Biosystems), were
maintained at 10-50 x 104 cells/mL in RPMI 1640 medium supplemented with 10% FBS,
100 gg/mL penicillin and 100 U/mL streptomycin. To prepare for cytotoxicity and
apoptosis assays, the cells were diluted to 10 x 104 cells/mL and distributed in 24-well
plates with 0.5 mL/well. The cells were treated with aqueous solutions of platinum
complexes for 19.5 h, then transferred to microcentrifuge tubes, pelleted and
resuspended in 20 gL of PBS. A 5 pL aliquot was combined with 5 tL of trypan blue
(0.4% in PBS) and counted under a light microscope. The remaining 15 gL sample was
fixed in 0.5 mL of cold methanol for 10 minutes and then pelleted. After a 5 min DAPI
(1 gg/mL in PBS) treatment, the cells were pelleted and mounted on glass slides in 10
JL of Mowiol mounting medium. The stained nuclei were counted under a
fluorescence microscope. All samples were prepared in duplicate.
For HeLa C27, colony counting cytotoxicity assays were performed as previously
described [35]. All samples were prepared in triplicate, and platinum concentrations
were verified by atomic absorption spectroscopy. For apoptosis assays, HeLa C27 cells
were distributed on 24-well plates 24 h prior to platinum treatment. After the
treatment, the supernatant medium was transferred to microcentrifuge tubes, and the
cells were washed with PBS, which was transferred to the same tubes. The cells were
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trypsinized, added to the tubes, pelleted and stained in the same manner as the Jurkat
C2 cells.
3.2.12 /-Lactamase expression assay in Jurkat cells
The p-lactamase assay was performed by Dr. Gregor Zlokarnik of Aurora
Biosystems according to the following protocol. Jurkat C2 cells in RPMI medium were
distributed into black 96 well clear-bottom microtiter plates at 100,000 cells per well.
The platinum complexes were dissolved at a concentration of 1 mM in water. Serial
dilutions of these solutions were prepared in water and added in 10% of final volume to
the cells. After a 20 h platinum treatment, the cells were induced with 100 RM
carbachol for 4 h. Cells were then loaded with 1 tM CCF2/AM at room temperature
for 1 h prior to fluorescence plate reading. The corrected signal from the blue channel
was divided by the signal from the green channel to obtain the final blue to green
intensity ratio. With the gain settings used for this experiment, a population with >95%
of the cells expressing p-lactamase gave a ratio of greater than 3.0 and a population of
with no cells expressing p-lactamase gave a ratio of 0.1-0.2. Jurkat cells constitutively
expressing P-lactamase under the control of the CMV early promoter (CMV-bla Jurkat)
were treated in the same manner as the C2 clone, but were kept 24 h in the incubator
without any induction period prior to dye loading. All samples were prepared in
quadruplicate, and the data were averaged with error bars representing standard error
(= standard deviation/square root of number of multiples).
3.3 Results
3.3.1 Constitutive EGFP expression in HeLa cells
The two putative pEGFP-N1 transfected HeLa clones appeared bright green under
a fluorescence microscope equipped with FITC filters, whereas the parental HeLa cell
line was invisible. It was concluded that both clones were constitutively expressing
EGFP under the control of the CMV promoter. To determine the effect of cisplatin on
CMV-driven constitutive EGFP expression, the fluorescence of the cells was measured
after cisplatin treatment. Table 3.1 shows that even toxic cisplatin concentrations did
not cause a marked decrease in EGFP fluorescence after 24 h. The half-life of the EGFP
in HeLa cells was determined by 35S labeling of proteins, followed by immuno-
precipitation. The autoradiogram in Figure 3.2 shows that the EGFP half-life is 20-30 h.
Chapter 3
Table 3.1: Relative fluorescence intensity (RFI) at 509 nm (395 nm excitation),
corrected for cell count, for HeLa cells after a 24 h 370 C cisplatin treatment.
[Cisplatin], M RFI/cells x 10-6: RFI/cells x 10- 6 : pEGFP-
parental HeLa Nl-transfected HeLa
0 1.03 5.89
1 1.47 6.56
5 1.88 5.87
10 (some cells dead) 1.80 5.98
40 (all cells dead) 1.33 4.93
Sparental HeLa I EGFP HeLa
kDa
220 --
97.4
66-
46---0
30 - 40 EGFP
Time(h) 0.25 1 4 7 21 30 0.25 1 4 7 21 30
Figure 3.2: SDS/PAGE analysis of immunoprecipitated 35S-labeled proteins from
parental and pEGFP-N1-transfected HeLa cells. The cells were pulsed with 35S and
then incubated for the indicated times. The extracts were precipitated with an anti-
GFP antibody.
3.3.2 Inducible EGFP expression in HeLa Tet-On cells
To generate HeLa cells with inducible EGFP expression, the pTRE-EGFP plasmid
was first cloned. Figure 3.3 shows that restriction digestion of pTRE-EGFP resulted in
fragments of the expected lengths. Automated DNA sequencing confirmed that the
desired plasmid had been obtained. HeLa Tet-On cells were transfected with pTRE-
EGFP, with the hygromycin resistance plasmid pTK-Hyg added to allow selection. By
fluorescence microscopy it appeared that at least 12 of the hygromycin-resistant clones
possessed doxycycline-inducible EGFP expression. The Western blot in Figure 3.4
confirmed that clones 27, 28 and 29 all expressed EGFP in the presence of doxycycline.
HeLa C27 was used for most subsequent EGFP induction studies. The time course of
doxycycline induction of EGFP fluorescence in HeLa C27 is plotted in Figure 3.5. A 13.5
h induction period provided sufficiently high fluorescence readings, which were
independent of doxycycline concentration over a range from 2.16 to 216 gM.
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Figure 3.3: Plasmid map and ethidium bromide stained agarose gel showing the
products of restriction digestion of pTRE-EGFP. Lane 1: Undigested plasmid. Lane
2: EcoRI/XbaI digest; 0.8 and 3.1 kb expected. Lane 3: BamHI digest; 0.8 and 3.1 kb
expected. Lane 4: NcoI/HindIII digest; 1.2 and 2.7 kb expected. Lane 5:
BamHI/HindIII digest; 0.5, 0.8 and 2.6 kb expected. Lane 6: DNA size standards.
pTRE-EGFP-transfected HeLa clones
29 28 27 26 251
kDa
4 67
4 56
4 42
4 28
4 23
4 17
Figure 3.4: Western blot of extracts from pTRE-EGFP-transfected HeLa cells, probed
with an anti-GFP antibody. Parental HeLa cells and crude recombinant GFPuv were
used as controls.
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Figure 3.5: Time course of EGFP induction in HeLa C27. Cells were treated with 21.6
gM doxycycline.
3.3.3 Effect of platinum complexes on EGFP expression in HeLa C27
HeLa C27 was initially exposed to platinum complexes under various condi-tions
to determine their effect on EGFP expression. For a 13.5 h induction, platinum was
added either 2 h before doxycycline ("pre-treatment") or at the same time as the
doxycycline ("co-treatment"). In a third protocol the cells were treated with platinum
for 2 h, washed, and then induced ("pre/wash"). Figure 3.6 shows that all three
methods of cisplatin treatment caused a dose-dependent decrease in EGFP expression.
The pre/wash condition required higher doses than pre-treatment or co-treatment to
obtain the same EGFP inhibition, as expected since platinum was not present in the
media for any of the 13.5 h induction period. Figure 3.7 shows that trans-DDP affected
EGFP expression in a manner distinct from cisplatin. At low trans-DDP concentrations,
there was a dose-dependent increase in EGFP, followed by a sharp decrease at very
high concentrations. To determine whether the dose-response results were unique to
HeLa C27, the 13.5 h co-treatment assay was repeated in HeLa Tet-On C28. Figure 3.8
shows that similar results were obtained in C28.
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Figure 3.6: Effect of cisplatin treatment on EGFP expression in HeLa C27. All
samples were induced with 21.6 gM doxycycline for 13.5 h. Fluorescence readings
were divided by total cellular protein and normalized to induced, unplatinated
control (100%).
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Figure 3.7: Effect of trans-DDP treatment on EGFP expression in HeLa C27. All
samples were induced with 21.6 gM doxycycline for 13.5 h.
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Figure 3.8: Effect of cis- or trans-DDP co-treatment on EGFP expression in HeLa C28.
The effect of a 13.5 h co-treatment with two major types of platinum complexes
was tested. The cis platinum complexes have chloride ligands in the cis configuration
and mimic cisplatin by inhibiting EGFP expression in a dose-dependent manner (Figure
3.9). The trans platinum complexes, with chlorides in the trans configuration, induced
EGFP expression at low doses and inhibited it at high doses in a manner similar to
trans-DDP (Figure 3.10).
---- cis-[PtNH 3 (NH2C6H11)C2
120 Cl
0 Cl -Pt -NH2
NH 3
- - - cis-[Pt(C3 H7NH2)2C12
80 r C1
o C -Pt -N
60 H 2
NH 2
U 40
S- Kplatin
20 CI
Cl -Pt 
-NH 2
0 50 100 150 200 250 300 350 O NH 3
[Platinum], M
Figure 3.9: Effect of cis platinum complexes on EGFP expression in HeLa C27.
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Figure 3.10: Effect of trans platinum complexes on EGFP expression in HeLa C27.
DAPI staining revealed that a 16.5 h treatment with 20 gM cisplatin induced
apoptosis in 50% of the C27 cells, e.g., ACs0=20 gM. After a 20 h treatment, the AC50 for
cisplatin was 16 jgM. Although trypan blue staining showed that a 20 h treatment with
360 pM trans-DDP killed more than 90% of the cells, under no conditions did trans-DDP
induce apoptosis in more than 15% of the HeLa C27 cells.
3.3.4 Effect of other cytotoxic treatments on EGFP expression in HeLa C27
To assess the generality of the results with platinum, HeLa C27 was treated with
several non-platinum cytotoxic agents. MMS, an alkylating agent, behaved like trans-
DDP, stimulating EGFP expression at low (<1 mM) doses and inhibiting it at high (>3
mM) doses (Figure 3.11). Similarly, a short (15-90 min) 450 C heat shock caused a time-
dependent increase in EGFP expression, whereas a 120 min treatment caused a decrease
(Figure 3.12). Calicheamicin, on the other hand, was similar to cisplatin in causing only
a decrease in EGFP expression (Figure 3.13).
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Figure 3.11: Effect of MMS on EGFP expression in HeLa C27. Cells were treated with
MMS in serum-free medium for 1.5 h, then washed and induced in complete
medium.
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Figure 3.12: Effect of 450 C heat shock on EGFP expression in HeLa C27. After the
heat shock the cells were induced at 370 C.
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Figure 3.13: Effect of calicheamicin on EGFP expression in HeLa C27. A methanol
solution (<1% total volume) of calicheamicin was added to the cells in PBS for a 15
min treatment. The cells were then washed and induced in complete medium.
3.3.5 Northern analysis of EGFP transcription in HeLa C27
To determine whether changes in EGFP expression occur at the transcriptional or
post-transcriptional level, HeLa C27 cells were treated with cytotoxic agents and
subjected to Northern analysis. Parallel cell samples were assayed for EGFP fluor-
escence. A separate control was prepared for MMS, with cells treated in serum-free
media for 1.5 h and then given fresh complete media before induction. As Figure 3.14
reveals, EGFP transcription was greatly enhanced by trans-DDP, MMS and heat shock
treatment and blocked by treatment with cisplatin. In addition to specific inhibition of
the EGFP, there was also an overall decrease in transcription in the cisplatin-treated
cells. The results summarized in Table 3.2 show that transcriptional effects account for
the changes in EGFP expression.
Untreated Heat Shock (min) MMS (mM) cisplatin (M) trans-DDP (jIM)
no dox I 60 90 I0 0.5 1 7  14 21 1f20 170 220
EGFP
GAPDH
Figure 3.14: Northern blot of RNA prepared from HeLa C27 cells treated with various
cytotoxic agents.
Chapter 3
Table 3.2: Summary of Northern blot results. Parallel HeLa C27 samples were treated
and analyzed separately for EGFP fluorescence and RNA.
Treatment Relative EGFP Relative
fluorescencea EGFP RNAb
None 1.0 1.0
Heat shock, 60 min 5.1 18.6
Heat shock, 90 min 1.4 16.3
None, MMS conditions 1.0 1.0
0.5 mM MMS 9.4 36.1
1.0 mM MMS 13.6 73.0
7 pLM cisplatin 0.8 0
14 pM cisplatin 0.7 0
21 pM cisplatin 0.7 0
120 p.M trans-DDP 2.5 5.4
170 pM trans-DDP 7.0 24.0
220 gM trans-DDP 4.2 2.6
a EGFP fluorescence samples were prepared in triplicate.
Fluorescence readings were divided by total protein to correct
for uneven cell plating.
b RNA was quantitated by phosphorimager analysis of the
Northern blot. All readings were normalized for loading by
using GAPDH results.
3.3.6 Effect of tsHMG on the cisplatin response of HeLa C27
Transient transfection was used to study the effect of an HMG-domain protein on
the cellular response to cisplatin. First, HeLa C27 cells were transfected with the
pcDNA3.1-tsHMG expression plasmid and induced with doxycycline to determine
whether transient transfection and doxycycline induction were compatible procedures.
Fluorescence measurements (data not shown) and Western analysis (Figure 3.15)
confirmed that tsHMG and EGFP could be simultaneously expressed. Next a 13.5 h
cisplatin co-treatment assay was performed. Cells were transfected both with
pcDNA3.1-tsHMG or with pcDNA3.1 as a control. Figure 3.16 shows that tsHMG
enhanced the inhibitory effect of cisplatin on EGFP expression.
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Figure 3.15: Western blot of HeLa C27 extracts after transient transfection with
pcDNA3.1-tsHMG (50 gg/10 cm plate), probed for tsHMG expression with an anti-
mtTFA antibody.
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Figure 3.16: Effect of tsHMG on cisplatin inhibition of EGFP expression in HeLa C27.
Cells were transfected with 6 gg of pcDNA3.1-tsHMG, or as a control, pcDNA3.1.
3.3.7 Effects of low-dose cisplatin treatment on EGFP expression
Although cisplatin treatment generally resulted in a dose-dependent decrease of
EGFP expression, Figure 3.17 shows that low concentrations of the drug caused a
modest increase in EGFP expression. The increase was two-fold after a 13.5 h co-
treatment with 1.7 gM cisplatin, falling to less than 1.5-fold after a 17.5 h co-treatment.
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Repetitions of this experiment showed consistent results but also consistently high
error. To study other time-dependent effects, HeLa C27 cells were treated with low
doses of cisplatin for short periods, then washed and incubated for a short time before
induction. The results shown in Figure 3.18 demonstrate the difficulties of such an
experiment. EGFP expression is highly dependent on the freshness of the growth
medium, with a difference of two hours changing expression by up to 30%.
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Figure 3.17: Increases in EGFP expression caused by low doses of cisplatin. HeLa C27
cells were cotreated with doxycycline and cisplatin and induced for the indicated
time.
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Figure 3.18: Effect of media changing on EGFP expression in HeLa C27. After a 4
hour cisplatin treatment, the cells were given fresh media and incubated for the
indicated time before the 13.5 hour doxycycline induction.
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3.3.8 Screening of platinum complexes by reporter gene assays
To test the potential utility of the EGFP assay as a screening method for new
drugs, the 13.5 h co-treatment protocol was employed to evaluate a series of known
platinum complexes. The compounds shown in Figure 3.19 are comparable in
cytotoxicity to cisplatin, and they all inhibited EGFP expression at low doses. Higher
concentrations of the moderately cytotoxic complexes shown in Figure 3.20 were
required to inhibit EGFP expression. The inactive platinum complexes shown in Figure
3.21 had little or no effect on EGFP expression.
100 - cis-[PtNH3 (NH 2 C6 H1 1)C12]
Cl
S80 ClPt NH2
U NH3
6 -- - cis-[Pt(en)C12]
S60 - Cl
--- I
SCl 
-Pt -NH 2
40 H 2
-
- - cis-[Pt(NH2 CH3 ) 2 C12]
20
Cl
C1 Pt -NH2CH 3
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Cl
Cl -Pt 
-NH 2
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Figure 3.19: Results of EGFP expression assay using highly cytotoxic platinum
complexes.
Chapter 3
-A-- Kplatin
Cl
Cl -Pt NH 2
0 NH
-B - Rplatin
Cl
I\ I
Cl -Pt -NH 2
H NH2
0 80 160 240 320 400 480 560 -0 - [PtNH3C13]P04
[Platinum], gM Cl ..
C -- Pt -- C P0O4 +
IN 3
Figure 3.20: Results of EGFP expression assay using moderately cytotoxic platinum
complexes.
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Figure 3.21: Results of EGFP expression assay using minimally cytotoxic platinum
complexes.
The 13.5 h co-treatment method was employed to measure IC50 values for various
platinum complexes, where IC50 is the platinum concentration at which EGFP
expression was reduced to 50% of control. Colony counting cytotoxicity assays were
used to measure the LC5 0 values for the same complexes, where LCso is the
concentration at which 50% of the cells failed to form colonies. Figure 3.22 plots the
correlation between LC5 0 and IC5 0 for the tested compounds.
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Figure 3.22: Comparison of IC50 versus LCs0 for a series of platinum complexes.
To study the activity of platinum complexes with another reporter gene assay,
Jurkat C2 cells were treated with cis-DDP, trans-DDP and K2[PtCl 4]. The carbachol-
dependent induction of 1-lactamase was quantitated by measuring the ratio of intact
and cleaved CCF2-AM substrate (Figure 3.23a). The IC5 0 was 8 jgM for cisplatin, but
neither trans-DDP nor tetrachloroplatinate blocked p-lactamase induction at
concentrations up to 100 jgM. The sensitivity of Jurkat C2 cells to cis- and trans-DDP
was measured by trypan blue and DAPI staining. A 19.5 h cisplatin treatment resulted
in an LC50 of 30 M and an AC5 0 of 15 gM. trans-DDP had an LC5 0 of 100 gM after 19.5 h,
but never caused apoptosis in more than 35% of the cells. The CCF2 cleavage assay was
repeated (Figure 3.23b) in the constitutively expressing CMV-bla-Jurkat cell line. In that
case, the IC5 0 was 10 JM for cisplatin, 100 [M for trans-DDP, and tetrachloroplatinate
did not affect P-lactamase expression.
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Figure 3.23: Effect of platinum treatment on P-lactamase expression, as measured by
CCF2 cleavage, in two Jurkat cell lines. A: C2 Jurkat cells were treated with
platinum for 20 hours and then induced with carbachol for 4 hours. B: CMV-bla
Jurkat cells were treated with platinum for 24 hours.
3.4 Discussion
3.4.1 Constitutive expression of EGFP in HeLa cells
In the cloned HeLa cell lines that constitutively expressed EGFP, no change in
EGFP fluorescence was observed upon treatment with cisplatin, even at concentrations
that killed the cells within 24 h. Because these cell lines express high levels of EGFP
with a half life of 20-30 h, the residual EGFP concentrations in the cells prior to cisplatin
treatment are probably sufficient to obscure any effect from platinum treatment.
Recently, a series of GFP mutants with short (2-3 h) half-lives was made commercially
available. These mutants may permit the use of constitutively expressed EGFP as a
reporter of platinum cytotoxic activity.
3.4.2 Inducible expression of EGFP in HeLa Tet-On cells
The effects of cytotoxic agents on EGFP expression in HeLa C27 cells were
surprising in that different agents yielded two distinct types of response. For one class
of cytotoxic agent, including trans-DDP, other trans platinum complexes, and, to a
greater extent, MMS and heat shock, EGFP expression rose sharply, reached a
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maximum, and then fell with increasing levels of damage. In the other class were
cisplatin, other cis platinum complexes, and calicheamicin, where a dose-dependent
decrease in EGFP expression occurred. Very low (<2 gM) concentrations of cisplatin
caused an approximately 200% increase in EGFP expression relative to the untreated
control, quite modest compared to the maximal values of 800%, 2100% and 2500% for
trans platinum complexes, MMS and heat shock, respectively. Northern analysis
revealed a correlation between EGFP fluorescence and transcription of the gene;
furthermore, cisplatin-treated cells had lower total RNA content than others, indicating
an overall transcriptional decrease. Although various forms of DNA damage can
increase or decrease reporter gene expression, there are no reports in which different
cytotoxic agents caused opposite effects on transcription from the same promoter.
There also are no examples of a single cytotoxic agent both enhancing and inhibiting
gene expression from the same promoter in a dose-dependent manner.
The contrasting effects were not a function of overall cytotoxicity. For example,
trans-[Pt(NH2CH3)2C12] caused a dose-dependent increase in EGFP expression, from one
to five times its LCs 0 value of 8 pgM. By contrast, [Pt(lysine)C12] brought about a dose-
dependent decrease at values ranging from 0.3-5 times its 70 pgM LC50 value. Apoptosis
cannot explain the different effects either. Apoptosis is not induced by trans-DDP, but it
is induced by heat shock [36,37], MMS [38], and JM 335, the platinum(IV) complex
shown in 3.9 [39], all of which stimulate EGFP expression. The results are also unlikely
to be a consequence of the specific site of integration of the TRE-EGFP construct into the
host genome since similar results were obtained with HeLa C28.
The upregulation of the EGFP by heat shock as well as DNA damaging agents
suggests that it is a general stress response. The mammalian stress response involves
the induction of many types of genes including heat shock proteins [40,41], stress
activated protein kinases (JNK SAPK) [42,43], the p53-dependent cell cycle arrest and
apoptosis pathway proteins, and DNA repair enzymes [15,16]. Although the Tet-On
gene expression system is not endogenous to mammalian cells, this artificial construct
could nonetheless also be activated by stress. The damage induced by cis platinum
complexes and calicheamicin must be different from other forms of stress. It is not
surprising that calicheamicin blocks gene expression, since it is a highly toxic com-
pound that enters cells, cleaves DNA and induces apoptosis in less than 4 h [44,45]. The
inhibition of EGFP transcription by many cis platinum complexes, of variable toxicity
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but all capable of forming 1,2-intrastrand DNA cross-links, suggests a structural effect.
The distortion of DNA (reviewed in [46]) induced by the 1,2-intrastrand cross-link
could lead to differential protein recognition, and thus transcriptional consequences of
cis platinum adducts compared to most other types of damage. The modest increase in
EGFP at low doses of cisplatin could result from the conflicting influences of stress
response and the unique structural consequences of its DNA adducts.
Cisplatin-DNA adducts are recognized by a variety of proteins [47], including
those involved in nucleotide excision repair (NER), DNA mismatch repair, and the
high-mobility group (HMG)-domain proteins. It seems unlikely that either of the repair
systems is responsible for the different transcriptional effects, since NER processes
trans-DDP intrastrand cross-links [48] and the mismatch repair pathway recognizes
MMS damage [49]. The HMG-domain proteins, which specifically recognize DNA
damaged with cis platinum complexes but not any of the other agents tested, could be
involved. HMG-domain proteins may contribute to cisplatin cytotoxicity by blocking
the repair of cisplatin-DNA adducts [50-53]. Repair blockage would cause cis platinum
adducts to be more persistent than other forms of DNA damage. If upregulation of the
EGFP is a response to stress in HeLa C27, however, then persistent DNA adducts might
be expected further to induce rather than to block EGFP expression, unless the shielding
is so effective that this damage is completely unrecognized.
It has also been proposed that cisplatin adducts could titrate HMG-domain
proteins away from their natural binding sites [54]. Because many HMG-domain
proteins serve as transcription factors, such an event could lead to cell death through
the misregulation of transcription [55]. If the transcription factors necessary for EGFP
induction specifically recognize cisplatin-DNA adducts, then stress- and doxycycline-
induced EGFP transcription would be prevented by cisplatin and its structural analogs.
This mechanism would also explain the modest increase in EGFP expression at low
levels of cisplatin. Only when a sufficient number of adducts formed would the
titration be effective.
The titration hypothesis also applies to non-HMG-domain transcription factors. It
was recently shown that the basal transcription factor TATA binding protein-TFIID
(TBP) recognizes both cisplatin- and UV-damaged DNA [56]. In a subsequent study
[57], DNA modified with a series of damaging agents was assayed for TBP binding and
for transcription inhibition in HeLa whole-cell extracts. For each type of adduct tested,
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TBP binding correlated with transcription inhibition, with cisplatin and cis-[Pt(dach)C12]
having strong effects. In some experiments, trans-DDP-modified DNA bound TBP and
inhibited transcription slightly, whereas MMS and [Pt(dien)Cl]C1 did neither. It was
proposed that the kinked DNA structure formed by cis platinum adducts resembles the
TBP binding site and can thus titrate the protein away from its normal transcriptional
activator region. These results are entirely consistent with the present EGFP expression
results, and the observation that trans-DDP enhances EGFP expression to a lesser extent
than MMS or heat shock could be explained by low-level transcription factor binding,
as observed in the TBP study.
3.4.3 Support for the repair shielding hypothesis
As mentioned in the previous section, HMG-domain proteins can mediate
cisplatin cytotoxicity by shielding the adducts from repair. This behavior was observed
in NER assays in which HMG-domain proteins inhibited the repair of the major
1,2-d(GpG) and d(ApG) intrastrand cisplatin-DNA adducts in vitro [51,53]. In
Saccharomyces cerevisiae, Ixrl, an HMG-domain protein, modulated the sensitivity of
yeast to cisplatin in a manner consistent with the shielding of the adducts from excision
repair [50,52]. It has also been reported that HMG2 overexpression sensitized lung
adenocarcinoma cells to cisplatin [58]. A recent study showed that expression of
tsHMG enhanced cisplatin-induced apoptosis in HeLa Tet-On cells [59]. This protein is
particularly interesting because cisplatin is especially effective against testicular tumors,
and tsHMG recognizes [60] and blocks the NER [53] of cisplatin adducts with unusually
high proclivity. To examine further the role of tsHMG in cisplatin cytotoxicity, the
EGFP induction assay was performed on HeLa C27 cells expressing tsHMG. Transient
transfection of C27 to express tsHMG augmented the cisplatin-dependent inhibition of
EGFP expression, especially at low platinum concentrations. Because tsHMG is not
normally expressed in HeLa cells, it is highly unlikely that this result is a consequence
of additional transcription factor hijacking. The results are best explained by the repair
shielding hypothesis. If the recognition of cisplatin-DNA adducts by transcription
factors prevented gene expression, then repair blockage by tsHMG could augment that
effect by allowing the damage to persist, as illustrated in Figure 3.24. As stated
previously [61], the two mechanisms are not mutually exclusive and may, in fact, be
synergistic.
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Figure 3.24: Proposed scheme to explain the effects of cytotoxic agents on EGFP
expression.
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Because the EGFP induction assay provides insight into the cellular processing of
platinum damage, it was expected that it could be used to study the time course of
damage recognition and repair. Technical considerations prevented the successful
execution of such experiments, however. Because the timing of media changes greatly
affected EGFP induction, it was difficult to compare the results of timed treatments and
recovery periods. Although the inducible reporter gene system was ideal for many of
the experiments reported in this chapter, a constitutively expressed reporter could
eliminate several variables for repair and recovery experiments.
3.4.4 The use of reporter gene assays for screening platinum complexes
The two reporter gene assays used in this chapter are both good methods for
screening platinum complexes to predict cytotoxicity. The EGFP induction assay
yielded a good correlation between LC50 and IC50 values for a series of known platinum
complexes. Although the EGFP method is much faster than any currently available
cytotoxicity assay, with results available 13-14 h after platinum treatment, it is not yet
suitable for high-throughput work. Modest levels of EGFP expression necessitate the
lysis of cells from a 35-mm well in a small volume of buffer, followed by transferal of
the lysate to smaller wells in order to intensify the fluorescence signal. With
improvements in inducible gene expression, GFP fluorescence intensity and
fluorescence detection methods, however, the assay could be adapted for high-
throughput screening. The p-lactamase CCF2/AM assay, which showed a dose-
dependent decrease in gene expression upon treatment with cisplatin but not with
ineffective platinum complexes, also surpasses existing cytotoxicity assays in speed.
The results are available within 24 h of platinum treatment, and the assay is performed
with the aid of robotics for high-throughput screening. The promising initial results
have inspired a collaborative effort to screen combinatorial libraries of platinum
complexes with the P-lactamase assay [62].
An additional advantage to both reporter gene assays is that they screen platinum
complexes for a biochemical effect, inhibition of gene expression, rather than measuring
cell death as an endpoint. In that sense, they are mechanism-based screening methods.
The major disadvantage is that both methods require stable cell lines expressing the
desired reporter genes, whereas cytotoxicity assays can be performed on any cultured
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cell line. Because it can take several months to clone stable transfectants, it is essential
to choose relevant cell lines for platinum drug screening.
3.5 Conclusions
The work described in this chapter was undertaken to develop new screening
methodologies for combinatorial libraries of platinum complexes. As the results for
both the EGFP and P-lactamase assays indicate, that goal was achieved with two fast
and convenient assays, one of which is already performed in a high-throughput
environment. These assays represent a new approach to cell-based screening of
platinum complexes, focusing on mechanistic events rather than cytotoxic endpoints.
In addition to developing new screening methods using reporter genes, this research
yielded some information on the mechanism of action of platinum anticancer drugs.
The results imply that the upregulation of EGFP transcription is a general stress
response in HeLa C27, and that the 1,2-intrastrand platinum-DNA cross-link is
recognized by one or more proteins in a manner that blocks the stress response and
down-regulates transcription. Although the identity of the recognition element(s) is not
known, the results are consistent with transcription factor binding to 1,2-intrastrand
platinum-DNA adducts. Whatever the mechanistic significance of the transcriptional
decrease may be, it is clearly a cellular response to cisplatin, so the effect of an HMG-
domain protein on that response was determined. The results, showing that tsHMG
steepened the dose-response curve, support the concept that HMG-domain proteins
block the repair of cisplatin adducts.
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Appendix A
Cloning and Purification of the Fusion Protein
HMG1-GFPuv
A.1 Introduction
The solution-phase assay described in Chapter 2 used a gel mobility shift assay to
identify from platinum-amino acid mixtures a compound, Kplatin, that forms 1,2-intra-
strand DNA cross-links specifically recognized by HMG1. The gel shift assay
effectively quantitates protein-DNA binding but has several limitations in its applica-
tion as a screening method for cytotoxic platinum complexes. For each set of platinum
complexes, the DNA must be platinated, precipitated and quantitated. After the
modified DNA is radiolabeled, a series of protein-DNA samples must be electro-
phoresed and the results analyzed with a phosphorimager. Not only are some of these
steps labor-intensive, but cost and safety considerations preclude the use of radio-
activity in high-throughput screening. A better approach would be to screen platinum
complexes on solid phase supports [1-3]. Solid phase methods allow compounds to be
identified by immobilization and position in a binding assay, and they can be
performed with the aid of robotics to increase throughput [4]. Macromolecular binding
assays frequently employ fluorescence [5] because fast and accurate detection methods
are available. Small fluorescent moieties often can modify proteins and nucleic acids
without disrupting structure and function. The scheme shown in Figure A.1 was
envisioned, whereby an HMG-domain protein could be labeled, and DNA covalently
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linked to a solid support, such that the binding of the fluorescent HMG-domain protein
to platinated DNA could be quantitated.
B. Allow platinum complex
A. Covalently link DNA to react with DNA.
to solid support.
D. Wash away unbound proteinC. Add fluorescently labeled and measure fluorescence.
HMG-domain protein.
Figure A.1: Proposed solid-phase method for screening platinum compounds for Pt-
DNA-HMG complex formation.
Amine or thiol groups on proteins can be chemically modified [5]. Lysine side
chains, of which there are many on HMG1, and N-terminal amines react with
isothiocyanates. Cysteine thiols can be modified by reaction with iodoacetamide.
Because HMGdomB contains only a single cysteine residue, the thiol should be free
under reducing conditions to react with a fluorescent label. In addition to these
synthetic approaches, it is also possible to label fluorescently a protein by expressing it
as a fusion with the GFP [6,7]. Although GFP fusions are typically expressed without
purification in cells or organisms, it was expected that an HMG1-GFP fusion could be
purified and used for screening methodologies. This appendix describes several
attempts to prepare fluorescently labeled HMG-domain proteins with native DNA-
binding activity.
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A.1 Experimental
A.1.1 Fluorescein isothiocyanate (FITC) labeling of HMG1.
A standard protocol for lysine modification was followed [8]. HMG1 was dia-
lyzed against FITC labeling buffer (50 mM boric acid, pH 9.2, 200 mM sodium chloride)
at 4C for 48 h. The dialyzed protein was spectrophotometrically quantitated by using
the approximation 1 OD280=0.74 mg/mL. FITC was weighed into a dry vial and dis-
solved in anhydrous dimethyl sulfoxide. A mixture of 28 gM HMG1 and 214 gM FITC
was stirred in the dark for 2 h; the protein was then transferred to a Microcon 10 device
and washed extensively with HMG1 storage buffer (50 mM Tris pH 7.3, 50 mM sodium
chloride, 5 mM 2-mercaptoethanol). The binding of modified HMG1 to 123-bp DNA
was assayed as previously described [9].
A.1.2 Fluorescent labeling of HMGdomB cysteine residues.
The Molecular Probes protocol for cysteine modification was followed [5]. A 1
mg sample of HMGdB was desalted in a Microcon 3 device (Amicon) and diluted in 2.2
mL of a degassed 50 mM Tris pH 7.5 buffer. In the dark, 112 gtL of a 20 mM solution of
4-iodoacetamidosalicylic acid was added dropwise to the protein solution. After the
reaction was stirred for 2 h at room temperature in the dark, excess reagent was con-
sumed by adding 5 gL of 1 M dithiothreitol (DTT). The protein was washed extensively
in a Microcon 3 device with a 50 mM NaC1, 50 mM Tris pH 7.5 buffer. The protein was
analyzed by UV/visible and fluorescence spectroscopy and by SDS/PAGE. The
fluorescently labeled HMGdomB was used in a gel shift assay with a 15-bp probe as
previously described [9]. After electrophoresis the gel was dried and quantitated on a
Molecular Dynamics PhosphorImager.
A.1.3 Cloning of the HMG1-GFPuv expression plasmid.
All enzymes were purchased from New England Biolabs unless otherwise
indicated. The following primers were used to amplify the HMG1 gene from the
HMG1 expression plasmid.
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Top HMG1-PCR: (boldface: HindIII site)
5'-GAAGGAGATATAAGCTTGGGCAAAGGAGATCCTAAGAAGCCG-3'
Bottom HMG1-PCR: (boldface: SmaI site)
3'-CTACTTCTTCTTCTACTACTACTACTTGGGGCCCCAAGATCGCGT-5'
The PCR reaction was performed by using an EZStart 100 reaction tube (Molecular Bio-
Products). To the prepared reaction tube, 0.2 gg of template DNA (pHMG1) and 0.5 Rg
of top and bottom primers were added, with 5 U of Pfu polymerase (Stratagene) in a
total volume of 50 gL. The reaction cycles were as follows:
1 cycle: 94°C, 45 s.
25 cycles: 94°C, 45 s; 55°C, 45 s; 720 C, 120 s.
1 cycle: 720 C, 600 s.
The PCR product was precipitated with ethanol and digested with HindIII and SmaI;
the enzymes were heat-inactivated and the products were used without further
purification.
The pGFPuv bacterial expression vector (Clontech) was amplified in E. coli and
purified with a Qiagen 500 plasmid purification kit. The plasmid was digested with
HindIII and SmaI, purified on a 1% agarose gel and precipitated with ethanol.
The HindIII/SmaI digest of the HMG1 PCR product was combined with the
HindIII/SmaI digest of pGFPuv and incubated for 16 h at 160C with T4 DNA ligase in
the presence of 10 gM ATP. The ligation mixture was transformed into chemically
competent XL1-Blue E. coli and plated on LB ampicillin agar plates. The resultant
colonies were inoculated into LB ampicillin media and grown to saturation; the
plasmids were isolated by the boiling lysis method. The plasmids were digested with
XhoI and NsiI and analyzed on a 1% agarose gel for the expected 1030-bp insert. Eight
colonies having the insert were subcloned on LB amp plates for further study. Two of
the plasmids were purified with a Qiagen-500 kit for restriction mapping and
sequencing. The putative pHMG1-GFPuv plasmids were digested with a series of
restriction enzymes to verify that the HMG1 gene had been properly inserted. The
products were analyzed on a 1% agarose gel. The two plasmids were submitted to the
MIT Biopolymers facility for automated DNA sequencing on the ABI Prism system.
The primers were as follows:
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Forward:
5'-ATAACAATTTCACACAGGAAACAGCTATGACCA-3'
Middle forward:
5'-GGCCGCCAAGCTGAAGGAGAAGTATGAGAAGGATATT-3'
Reverse:
3'-TACTCATTTCCTCTTCTTGAAAAGTGACCTCAA-5'
Middle reverse:
3'-GGGTTCTCCGGAGGAAGCCGGAAGAAGAACAAGACA-5'
A.1.4 Expression and purification of HMG1-GFPuv.
The pHMG1-GFPuv-1 plasmid was transformed into BL21DE3 E. coli by
electroporation. The bacteria were plated on LB ampicillin agar plates and one
resulting colony was inoculated into 250 mL of LB ampicillin media. The starter culture
was grown to saturation and then inoculated into eight prewarmed 500-mL flasks of LB
ampicillin. After 3 h of shaking at 37C, the OD600 was 0.6 and the protein expression
was induced with 0.5 mg/mL of IPTG; the cells were shaken for an additional 3 h at
37 0 C. The cells were harvested by centrifugation (5000 x g, 15 min) and resuspended in
100 mL of solution A (described below) containing 1mg/mL Pefablock. The bacteria
were lysed by sonication and the cell debris was cleared by ultracentrifugation (40
krpm, 30 min, Beckman 45Ti rotor).
The purification method was an adaptation of a recent successful HMG1-GFPuv
purification [10]. The solutions used for column chromatography all contained 2.5%
(v/v) glycerol, 5 mM DTT, 0.025% (v/v) NP40, 0.025% (v/v) Tween 80. In addition, the
solutions contained the following: A, 1 mM MgC12 and 10 mM NaCl; B, 300 mM MgCl 2
and 50 mM NaC1; C, 10 mM NaC1; D, 100 mM potassium phosphate pH 7.4 and 10 mM
NaC1; E, 300 mM potassium phosphate pH 7.4 and 10 mM NaC1.
The crude protein solution was loaded at 2 mL/min onto a 12 cm long, 3 cm
diameter hydroxyapatite column that was pre-equilibrated in solution A. The column-
bound protein was washed with solution A until no UV absorbance was detected; it
was then washed with solution B for 1 h at 2 mL/min. The column was then washed
with one column volume of solution C and then with solution D. When green protein
began to elute from the column, 4-mL fractions were collected; more fractions were
collected as a gradient from 100:0 to 0:100 D:E gradient was run. The green fractions
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were analyzed by SDS/PAGE and the gels were stained with SYPRO Orange (BioRad)
and photographed with a Polaroid camera equipped with a transilluminator. All of the
fractions containing an approximately 60 kDa protein were pooled, concentrated in
Centriprep 10 devices (Amicon), and diluted into 30 mL of solution D.
The hydroxyapatite column was washed with 100 mL of solution E and was then
equilibrated with 200 mL of solution D. The partially purified HMG1-GFPuv was
loaded on the column at 2 mL/min and washed with 120 mL of solution D. The protein
was then eluted first with a linear gradient from 100:0 to 30:70 D:E, 2 mL/min, over 40
min. Further elution was accomplished by a second linear gradient from 30:70 to 100:0
D:E, 2 mL/min, 100 min. The remaining protein was eluted by washing the column
with solution E for 20 min at 2 mL/min. The protein was collected in 4-mL fractions;
the fractions were analyzed on SDS gels stained with SYPRO Orange.
The fractions that contained a 60-kDa product were pooled, concentrated in
Centriprep 10 devices and diluted in 10 mL of FPLC buffer (150 mM potassium
phosphate pH 7.4, 0.025% NP40, 0.025% Tween 80, 5 mM DTT). A Superdex 75 column
was washed in 400 mL of degassed FPLC buffer at 1.5 mL/min. The protein was
loaded onto the column and eluted at 1.5 mL/min with 4 mL fractions collected. The
fractions were analyzed on an SDS gel, and the two visibly green fractions, which
contained the 60-kDa protein, were concentrated in a Centricon 30 device and
exchanged into a 50 mM Tris pH 7.5, 50 mM NaC1 buffer. The final protein sample was
quantitated by UV/visible spectrophotometry and stored at a concentration of 10
mg/mL in frozen aliquots.
A gel shift assay to measure the binding of platinated 123-bp DNA to HMG1-
GFPuv was performed as previously described [9]. The excitation and emission spectra
of solutions of HMG1-GFPuv and GFPuv were recorded on a Hitachi F-3010
fluorescence spectrophotometer.
A.1.5 Expression and purification of GFPuv
The solutions used for GFPuv purification all contained 5% (v/v) glycerol, 1 mM
DTT, 0.01% (v/v) NP40. In addition, the solutions contained the following: A, 1 mM
MgCl 2 and 10 mM NaC1; B, 300 mM MgC12 and 50 mM NaCl; C, 10 mM NaC1, 10 mM
MgC12 and 100 mM potassium phosphate pH 7.4. GFPuv was overexpressed from the
pGFPuv plasmid in E. coli in the same manner as HMG1-GFPuv. The cells were lysed
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in solution A. The crude protein solution was loaded at 2 mL/min onto a 12 cm long, 3
cm diameter hydroxyapatite column that was pre-equilibrated in solution A. The
column-bound protein was washed with solution A until no UV absorbance was
detected; it was then washed with solution B for one hour at 2 mL/min. A linear
gradient from 100% B to 100% C was run, with 80 4-mL fractions collected. The green
fractions were analyzed by SDS/PAGE and the gels were stained with SYPRO Orange.
The fractions containing a pure 30-kDa protein were pooled and concentrated in an
Ultrafree 15 device (Millipore).
A.2 Results
A.2.1 Modification of HMG1 with FITC
As Figure A.2 shows, the reaction of HMG1 with FITC inhibited its specific
recognition of cisplatin-modified DNA. Even doubling the usual HMG1 concentration
did not result in protein-DNA binding.
Protein-DNA
complex
Free DNA - - .
Cisplatin - + + +
HMG-1 - - unmodified FITC-modified FITC-modified
1.0 lg 1.2 gg 2.4 g
Figure A.2: Gel mobility shift assay comparing the binding of 123-bp DNA to HMG1
and lysine-modified HMG1.
A.2.2 Modification of HMGdomB with 4-iodoacetamidosalicylic acid
The UV/visible spectrum of labeled HMGdomB had a shoulder at 300 nm,
where the dye absorbs. The dye: protein ratio, calculated from the relative absorbances
and extinction coefficients, was 0.38. Fluorescence spectroscopy confirmed the presence
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of the salicylic acid label on the protein; upon excitation at 304 nm, the protein had the
expected 400 nm emission. The labeled protein ran like HMGdomB on an SDS poly-
acrylamide gel; this result was expected since the label should have added only 321 Da
to the protein molecular weight. Figure A.3 shows the results of a gel mobility shift
assay comparing the DNA binding of unmodified and modified HMGdomB.
results are quantitated in Table A.1. The DNA-binding ability of HMGdomB was
inhibited by the presence of the fluorescent label; the magnitude of inhibition was
comparable to the degree of labeling of the protein (38%).
Protein-DNA
complex
4 Free DNA
cisplatin
equiv HMGdB
- + - - + + + - - + + +
0 0 5 10 25 5 10 25 5 10 25 5 10 25
Figure A.3: Gel mobility shift assay comparing the binding of a 15-bp platinated
DNA duplex to HMGdomB and cysteine-modified HMGdomB. The DNA was used
at a final concentration of 20 nM.
Table A.I: Binding of HMGdB and cysteine-modified HM
duplex.
GdB to a 15-bp DNA
Unlabeled HMGdB, Labeled HMGdB, % Shift, % Shift, cisplatin-
tM 4M unplatinated DNA modified DNA
0.10 0 28 52
0.20 0 34 56
0.50 0 45 59
0 0.10 7 33
0 0.20 9 37
0 0.50 13 48
A.2.3 Cloning of the HMG1-GFPuv expression plasmid.
The ligation of the HMG1 gene into HindIII/SmaI-digested pGFPuv, and
subsequent transformation of the reaction mix into XL1-Blue cells, resulted in approx-
imately 100 ampicillin-resistant colonies. The 64 colonies that were selected and grown
The
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in 2 mL of LB ampicillin media were harvested by centrifugation and inspected under
longwave ultraviolet light. Three classes of cell pellets were observed: 22 non-
fluorescent, 26 bright green fluorescent, and 16 moderately green fluorescent. The
plasmid DNA that was isolated from several members of each group was analyzed for
the presence of the desired insert. The 1030-bp NsiI/XhoI insert that was expected for
plasmids encoding the HMG1-GFPuv fusion protein was observed only in the DNA
derived from moderately green fluorescent colonies.
Figure A.4 shows the results of restriction mapping of two putative pHMG1-
GFPuv plasmids. The digestions with various restriction enzymes resulted in frag-
ments of the expected lengths. Two putative pHMG1-GFPuv plasmids were submitted
for sequencing with four primers: forward, reverse, middle forward, and middle
reverse. It was necessary to use primers that started at the middle of the HMG1 insert
in order to verify the correct sequence of the lengthy 640-bp insert. The sequencing
results confirmed that pHMG1-GFPuv-7 had no mutations.
12 3 4 5 6 7
10
8
6
4
2
1.5
15 pHMG1-GFPuv-2
0.75 . _
10
8
6
4
2 p
1.5 pHMG1-GFPuv-71.5-
0.75
0.4
Figure A.4: Ethidium bromide-stained agarose gel showing the restriction digestion
products of two HMG1-GFPuv plasmids. Lane 1: DNA size standards in kilobases.
Lane 2: Undigested plasmid. Lane 3: NsiI digest; 3.9 kb expected. Lane 4:
Stul/HindIII digest; 2.4 and 1.5 kb expected. Lane 5: SmaI/HindIII digest; 3.3 kb
and 0.64 kb expected. Lane 6: NdeI digest; 2.3, 0.85 and 0.76 kb expected. Lane 7:
BamHI digest; 3.9 kb expected.
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A.2.4 Expression and Purification of the HMG1-GFPuv Fusion Protein.
Figure A.5a shows that two rounds of hydroxyapatite chromatography resulted in
HMG1-GFPuv with three major impurities, all less than 45 kDa. Figure A.5b shows that
gel filtration FPLC removed most of the impurities from the fusion protein; the over-
loaded lanes (9-10) show that the protein is more than 90% pure.
1 2 3 4 5 6 7 8 9 10 11 1213 14 15161718 19 20
kDa
97.4
a45-
31-
22.5--
14-
1 2 3 4 5 6 7 8 910
kDa
97.4-
6 6 b
45-
31
22 -
14 -
Figure A.5: SYPRO Orange-stained SDS-PAGE gels showing the purification of
HMG1-GFPuv. A.5a: Results of hydroxyapatite chromatography (second round) of
HMG1-GFPuv. Lanes 1 and 15: Molecular weight markers. Lanes 2-14 and 16-20:
Samples of fractions eluted from the hydroxyapatite column in a phosphate gradient.
The fractions in lanes 5-14 and 16-19 were pooled. A.5b: Results of Superdex 75 size
exclusion FPLC chromatography of hydroxyapatite-purified HMG1-GFPuv. Lane 1:
Molecular weight markers. Lanes 2-6: Samples of fractions eluted from the
Superdex column. Lane 7: Previously purified HMG1-GFPuv. Lane 8: GFPuv. Lane
9: Sample from lane 3, overloaded. Lane 10: Sample from lane 4, overloaded. The
fractions in lanes 3-4 were pooled.
The fluorescence spectra of HMG1-GFPuv are shown in Figure A.6. The 395 nm
excitation maximum and 509 nm emission maximum were identical to those observed
for GFPuv (data not shown). Like HMG1, the fusion protein bound specifically to
cisplatin-modified DNA as shown in Figure A.7. A control experiment (data not
shown) confirmed that GFPuv had no specific interaction with DNA.
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HMG1-GFPuv excitation spectrum, emission at 509 nm
0 L
300
HMG1-GFPuv emission spectrum, excitation at 395 nm
300
250
200
150
100
I I I i 0 L-
350 400 450 500 400 450 500 550 600
Wavelength (nm) Wavelength (nm)
Figure A.6: Fluorescence spectra of HMG1-GFPuv.
- Protein-DNA complexes
4- Free DNA
cisplatin
protein (gg)
- + - + + +
0 0 0.8 1.5 0.8 1.5 1.5 5 1.5 5
I II I
HMG1 HMG1-GFPuv
Figure A.7: Gel mobility shift assay comparing the
and HMG1-GFPul
binding of 123-bp DNA to HMG1
A.2.5 Expression and Purification of GFPuv.
Figure A.8 shows that GFPuv was purified (>90%) by hydroxyapatite chromato-
graphy. The GFPuv was used as a control in experiments assessing the activity of
HMG1-GFPuv.
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Figure A.8: SYPRO Orange stained SDS-PAGE gel showing the purification of
GFPuv. Lane 1: Molecular weight markers. Lanes 2-7: Samples of fractions eluted
from the hydroxyapatite column in a phosphate gradient. Lane 8: Previously
purified GFPuv.
A.3 Discussion
The two attempts to modify HMG domain proteins chemically yielded products
that did not recognize cisplatin-modified DNA. It seems plausible that lysine modifica-
tion could inactivate HMG1 by preventing charge interactions necessary for binding
anionic DNA [11]. The modification of the sole cysteine in HMGdomB could interfere
with a critical structural or functional role of the residue. The expression of the HMG1-
GFPuv fusion protein was more successful. HMG1 was not expected to affect the GFP
fluorophore, which is well-shielded by the -barrel structure of the surrounding protein
[12]. The GFPuv was fused to the C-terminus of HMG1 in order to avoid disrupting the
basic N-terminal region believed to be important for DNA binding. Early attempts to
purify HMG1-GFPuv were complicated by the susceptibility of the linker region to
protease degradation and also by the tendency of the GFPuv subunit to self-associate
[10]. The hydroxyapatite protocol was much more successful than ion exchange, hydro-
phobic interaction, DNA affinity, or heparin chromatography. The resulting protein
was a DNA-binding, fluorescent fusion of HMG1 and GFPuv.
As described in Section 1.2, HMG1-GFPuv has been used in a solid-phase assay
to quantitate Pt-DNA-HMG1 binding [13]. Although this protocol is not yet optimized
for high-throughput screening, it has demonstrated the utility of fluorescently labeled
proteins in solid-phase screening methods.
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